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ABSTRACT
The purpose of this phenomenological study has been to discover, describe, and
understand the attitudes of Licensed Addictions Counselor’s (LACs) in treating cannabis
use disorders by accessing their lived clinical experiences, and discover what regulatory,
personal, environmental, social, scientific, legal, or other clinical experiences influence
the decision making of LACs who treat cannabis use disorders in Colorado. This study
sought to discover the attitudes, interactions, feelings, and other unique factors that form
the underlying assumptions, through reciprocal determinism, that inform clinical
decision-making choices independently. These dynamics have been ignored in the
literature and this study seeks to pursue it with practitioners directly to surface vital data
that has not appeared in the literature concerning the treatment of cannabis use disorders.
The research findings include information from practitioners concerning best practices in
the treatment of Cannabis Use Disorder, but this is largely theoretical and not derived
from accessing the attitudes and experiences of clinicians. The attitudes, clinical
experiences, and practices of substance use disorder (SUD) treatment providers have
been neglected, and yet legalization and approval of medical and recreational marijuana
may be of critical impact upon their clinical practice.
Keywords: cannabis use disorders, treatment of cannabis use disorders, clinician’s
attitudes and experiences toward treatment cannabis disorders, treatment of cannabis
use.
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CHAPTER ONE: INTRODUCTION
Overview
In this study, I provide information revealing some of the attitudes and practices
for addictions counselors following the legalization of marijuana for medical and
recreational use in Colorado. I present the time frames of the legalization followed by
statistics on increases in violent crime, motor vehicle traffic fatalities, and specific mental
health implications associated with marijuana use in Colorado. I also offer information on
the societal costs and effects of legalized marijuana including the toll to the healthcare
system, the relationship to trauma and legalization, as well as national trends of
marijuana use. I will present the effects on youth since the legalization of marijuana as it
relates to delinquency and marijuana use patterns of adolescents in Colorado, along with
significant medical implications for marijuana including emergency room visits, and
public health and environmental influences including risks of developing psychotic
disorders, maternal use of marijuana during pregnancy, lung cancer, risk of heart attack
and stroke, cyclical vomiting (i.e., cannabinoid hyperemesis syndrome), and the use of
marijuana as a replacement for opioids. The implications of marijuana use present known
risks in the literature, which I provided, as well as how marijuana and its intoxicating
effects operate within the endocannabinoid system. I survey the neurobiology of
marijuana addiction and withdrawal, followed by the risks and prevalence of cannabis
use disorders (CUDs), and briefly explore the known efficacy of medical marijuana along
with a summary of the adverse effects of marijuana. Finally, I review the treatment of
marijuana addiction and best practices including biblical counseling and marijuana, along
with the attitudes of medical and recreational marijuana among substance-use clinicians.
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Background
Literature focused on interventions following the legalization of marijuana in
Colorado became void of the attitudes and practices of addictions counselors regarding
the treatment of cannabis use disorders. The use of medical and recreational marijuana
presents risks of adverse consequences. Based on cultural changes, the long-standing
singular treatment goal of abstinence from all drugs, except nicotine and caffeine,
challenged the legitimacy of marijuana use for medical conditions. Substance use
disorder (SUD) clinicians demonstrated ambivalence towards the use of cannabis for
those who accepted treatment goals that do not include abstinence. They found it very
difficult to differentiate between the effects of medical and recreational marijuana use.
By contrast, skeptical of using marijuana for medical purposes, some clinicians believed
the medical use of marijuana justified recreational use. Van Boekel et al. (2013) found
substance use clinicians’ attitudes towards patients who test positive for marijuana
resulted in poorer quality care. Understanding generally accepted best practices among
clinicians in Colorado could improve by sampling and recording their therapeutic
experiences, attitudes, and actions, particularly those with licensure. A major
presupposition of this study was after the legalization Colorado potentially represented
one of the most important laboratories for observing the phenomenon of marijuana use
and its treatment implications. The current training and practice of addictions counseling
in Colorado include a harm reduction model, which acknowledges both licit and illicit
levels of drug use in our society. Using the approach, treatment providers sought to
correlate treatment goals with reducing adverse consequences. Rather than solely
measuring drug consumption, harm reduction treatment models support reducing the
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problems associated with certain behaviors beyond mere abstinence-only interventions
(Wodak,1999). Engaging with the lived clinical attitudes and experiences of licensed
addictions counselors in Colorado can assist in building consensus about effective
treatment and best practices along with developing community-based strategies to
prevent cannabis use disorders. One of the purposes of studying treatment implications
for addictions counselors’ post-legalization in Colorado acknowledges them as untapped
sources of observation, and data synthetization. They can produce meaningful
information concerning trends, themes, and patterns influencing addictions counseling.
Situation to Self
The motivation for conducting this study connects to my desire for exploring and
understanding the lived experiences of licensed addiction counselors engaged in treating
cannabis use disorders in Colorado. This study aligns with my personal shared
philosophical assumptions guided by constructivism, which form a methodological
strategy for testing claims and gaining knowledge (Merriam, 2009). In recognizing the
impossibility of conducting bias-free research, I selected the qualitative research design,
which focuses more on interpreting phenomena and understanding the constructs
surrounding the lived experiences of clinicians, rather than disproving or proving their
experiences by measurement. As the researcher engaged in this study, I assume both the
role of research instrument and reviewer in the study (Denzin & Lincoln, 2005). The
desire to seek and obtain new knowledge contributing to the base of pastoral and
community counseling research guided the study and facilitated implementing a generic
qualitative research methodological approach and design.
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Problem Statement
The problem is the need to fill a gap in existing knowledge of the clinical
experiences and attitudes of addictions counselors who play an important role as
gatekeepers to keep clients safe. They also act as harm reduction agents. I sought to
gather insights from clinicians’ attitudes and experiences, to assist them in making
informed decisions about the treatment of marijuana-related behavioral health problems.
Ultimately, I intended to contribute to improved treatment outcomes through recursively
reviewing and improving addictions counseling therapeutics.
Purpose Statement
The purpose of this study was to sample the attitudes and lived experiences of
addictions counselors who intervene with populations diagnosed with substance use
disorders but remain neglected in the professional literature (Wildberger & Katz, 2019).
A phenomenological study could help service providers discover, describe, and
understand the attitudes of Colorado LACs in treating cannabis use disorders. Accessing
their lived clinical experiences might enable them in discovering what regulatory,
personal, environmental, social, scientific, legal, or other factors influence their decision
making. Because social systems contain mechanisms of personal agencies, and clinicians
develop actions to achieve efficacious treatments, I selected the reciprocal determinism
theory as the guide for this study (Bandura, 2006). This theoretical framework supported
discovering the attitudes, interactions, feelings, and other unique factors clinicians use to
form their underlying assumptions and make clinical decisions independently.
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Significance of the Study
Throughout this study, I examine the personal and environmental factors that
reciprocally influence thought and behavior. I was unable to locate literature containing
information nor derived knowledge about the lived experiences of LACs treating
cannabis use disorders in Colorado or the interpersonal interactions of practitioners. Once
considered as vitally connected to their expectations, their clinical behavior ultimately
reflected their beliefs, goals, and feelings (Bandura, 1986, 1989, 2001). When social
interactions connect to personal characteristics, the relationship between them influences
human beliefs, emotional reactions, expectations, and cognitive abilities. Based on one’s
social status, personal factors can prompt highly variable reactions. This activates
emotional reactions through which modeling, education, and social persuasion
operationalize (Bandura, 1986).
Informing the attitudes and experiences of LACs who treat cannabis use disorders
following the legalization of marijuana for both recreational and medical use, including
considering the personal, environmental, and sociopolitical influences for them. The
theory of reciprocal determinism could assist in accessing the attitudes and experiences
resulting in treatment planning and the formulation of diagnoses for LACs. Providing this
knowledge potentially supports identifying key treatment themes, and new explanations
of the various dynamic interactions that combine when determining the behavior of LACs
who treat CUDs (Bandura (1986, 1989).
Research Questions
The overarching research questions were:
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RQ1. What are the personal attitudes of Licensed Addiction Counselors (LACs)
in Colorado concerning the treatment of Cannabis Use Disorders (CUDs)?
RQ2. What regulatory, personal, environmental, social, scientific, legal, or
clinical experiences influence the decision-making of LACs who treat
cannabis use disorders in Colorado?
Probing the Personal Attitudes of LACs
The intent of posing the first question was to collect data from LACs that probed
their current personal attitudes in treating CUDs in Colorado. Accomplishing this
required accessing each participants’ clinical context questions establishing how the
participant’s attitudes developed within their experiences (Merriam, 2009). Broadly
understanding the factors determinative for participants in making informed decisions
about treating CUD required supporting the development of the first question by
accessing the perceived experiences of participating LACs. Designing the second
question would contribute to answering to what extent, through exploring and analyzing
whether LACs behaviors, training, interpersonal clinical experiences, and especially
external factors influence their treatment of CUDs in Colorado (Creswell, 2009).
Perceptions of Experience
Both research questions promoted accessing the perceived experiences and
attitudes of participating LACs to broadly understand the determinative factors for
participants in making informed decisions about treating CUD. A phenomenological
perception of clinician’s cannabis treatment perspectives exists regardless of others’
views. I examined the methods used by clinicians to reveal how they make sense of their
clinical experiences, shape their worldview, and influence their behavior and counseling
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methods (Al-Busaidi, 2008). Both research questions probe the lived experience of LACs
in Colorado through reciprocal determinism and mechanisms of personal agencies that
exist within social learning systems by individuals who develop actions to achieve
desired ends (Bandura, 2006). Interactions with counselees provided an understanding of
how they describe clinical experiences, as these critical linkages are not predictable nor
spontaneous. In asking both research questions, I sought to gain a new understanding and
identification of causal factors that prompt and influence a clinician’s actions and, in turn,
activate reciprocal responses. The underlying assumptions of reciprocal determinism
organized clinicians’ decision-making processes as they choose intervention modalities
differentially and quite independently (Bandura, 2006).
Summary
The attitudes and practices of addictions counselors regarding the treatment of
cannabis use disorders remain neglected in the therapeutic literature documented
following the legalization of marijuana in Colorado. Researchers overlooked revealing
the attitudes, practices, or lived experiences of LACs as they encounter and treat CUD.
Accessing the lived clinical attitudes and experiences of licensed addictions counselors in
Colorado can help build consensus about effective treatment and best practices while
developing community-based strategies for the prevention of CUD. Colorado’s licensed
addictions professionals represent an untapped source for observing the effects of
marijuana and synthesizing meaningful data concerning trends, themes, and patterns
influencing addictions counseling.
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CHAPTER TWO: LITERATURE REVIEW
Overview
In reviewing the literature, I explored the current treatment environment for
addictions counselors following the legalization of marijuana. To discover
misconceptions, bias, and gaps in the treatment of cannabis use disorders as the adverse
effects become clearer, I considered prior studies regarding mental health factors,
medical effects, social outcomes, and adverse consequences. There is a need for
treatment goals developed by clinicians that move away from abstinence-only to a less
naïve reality, accepting marijuana use as inevitable and increasingly lawful. Minimal
literature exists that reveals the attitudes and practices of addictions counselors drawn
from their clinical experiences in the area of cannabis use disorders. My review unveils
consequences not previously predicted or known since the legalization of marijuana in
Colorado. I considered the risks, consequences, prevalence, current treatments, and
clinicians’ attitudes toward treating CUDs to underscore the critical need for addictions
counselors' ongoing awareness of the findings from science concerning the development
of CUDs. In furtherance of knowledge of the treatment of cannabis use disorders since
legalization, I also explored the implications for prevention and community-based
treatments informed by research and clinical experience coupled with attitudes of
licensed addictions counselors.
Theoretical Framework
I used a qualitative, phenomenological research design to identify new
information for the community of licensed addictions counselors in Colorado since the
legalization of marijuana for medical and non-medical purposes. in conducting this study,
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I focused on the personal attitudes and lived clinical and personal experiences of those
clinicians selected as study participants. The research questions served as the foundation
for the inquiry, and a qualitative approach guided the methodology for collecting and
analyzing data (Merriam, 2009). The participants shared a common interest in treating
cannabis use disorders or similar experiences relevant to the research topic.
A phenomenological perception of clinician’s cannabis treatment perspectives
exists regardless of other providers' views. Using a phenomenological approach, I
examined the clinical methods used reflective of their experiences and how they
influenced their behavior and counseling techniques (Al-Busaidi, 2008).
Reciprocal Determinism
The main theory framing this study was reciprocal determinism. The concept
supports unearthing the mechanisms of personal agencies that exist within social systems,
which reciprocally help individuals develop actions to achieve desired ends (Bandura,
2006). Interactions with counselees do not occur spontaneously or linearly and
predictably. Causal factors prompt and guide a clinician’s actions, and these, in turn,
activate reciprocal responses. The underlying assumptions of reciprocal determinism
organize clinicians’ decision-making processes as they choose intervention modalities
independently. Clinicians work within a “dynamic self” in which unique factors and
influences all contribute to the attitudes, feelings, and interactions with clients (Bandura,
1986, 1989, 2001, 2006).
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Related Literature
Marijuana Legalization Time Frames in Colorado
During the years 2000 to 2008, Colorado passed Amendment 20 to the Colorado
State Constitution, permitting a qualified medical patient and/or caregiver to possess up
to two ounces of marijuana and grow up to six marijuana plants for medical purposes.
Characterizing this time frame was 1,000-4,800 medical marijuana cardholders and no
dispensaries operating in Colorado (RMHIDTA, 2019).
From 2009 to the present marks the legalization through the medical marijuana
commercial industry. In 2012 there were 100,000 medical marijuana cardholders and 500
licensed dispensaries operating in Colorado, as well as licensed edible manufacturers and
plant cultivation operations. The legalization of marijuana for recreational purposes for
those who are over 21 permitted the creation of marijuana retail stores, cultivation
operations, edibles, and the marijuana retail business, which began operations on January
1, 2014 (RMHIDTA, 2019).
Traffic Fatalities, Impaired Driving
Licensed Addiction Counselors (LACs) in Colorado operate licensed facilitates to
intervene with people arrested for criminal offenses including driving under the influence
of drugs (DUID). Addiction counselors provide treatment for marijuana-related
offenders, which includes mandated psychoeducation. In Colorado, addictions counselors
make informed decisions about treatment issues and highlight the increase of traffic
fatalities and impaired driving as causal factors. Following the legalization of recreational
marijuana use, traffic deaths in which drivers tested positive for marijuana increased
109% while all Colorado traffic deaths increased 31%. Also, traffic deaths involving
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drivers who tested positive for marijuana more than doubled from 55 in 2013 to 115
people killed in 2018. This equates to one person killed every three days in 2018
compared to one person killed every six and a half days in 2013 (National Highway
Traffic Safety Administration, 2019). This is the overarching theme related to marijuana
treatment implications because of the strong correlation with dramatic increases in
mortality (death rates) since legalization. In other words, this trend connects to lethality
(National Highway Traffic Safety Administration, 2019).
In 2018, a total of 632 traffic deaths occurred, of which:
• 396 were drivers
•

124 were passengers

•

89 were pedestrians

•

22 were bicyclists

•

One was a personal conveyance (Colorado Department of Transportation,
2019).

Some of the most significant current developments related to addictions and
implications for treatment relate to mortality and risks of death or serious injury. In 2018,
of the 109 drivers in fatal wrecks who tested positive for marijuana use, 83 tested positive
for Delta 9 tetrahydrocannabinol, or THC, the psychoactive ingredient in marijuana, in
their blood. This indicates they used marijuana within hours of the accident, according to
state data. Of those, 43% tested over 5 nanograms per milliliter, the state permissible
inference level for driving (RMHIDTA, 2019).
Colorado Toxicology Results of Marijuana-Related Fatal Crashes (Operators)
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Co-morbidity (i.e., drug combinations) for operators who were reportedly
involved in a fatal crash in 2018, and who tested positive for Marijuana (i.e., THC), a)
13% marijuana only, b) 30% marijuana and alcohol, c) 30% marijuana and other drugs
(no alcohol involved) and d) 13% marijuana, other drugs, and alcohol (National Highway
Traffic Safety Administration, 2019). The court orders probationers in Colorado to
undergo drug testing. However, they can use marijuana while on probation if they have a
medical marijuana card. About 20-30% of probationers ages 14 -25 years old tested
positive three or more times in Colorado, and approximately 18% of probationers over 26
years old tested positive three or more times (Colorado State Judicial Branch, 2018).
Addiction counselors receive training on the use of presumptive screening testing
protocols, including portable breath tests for alcohol. Arresting a driver in Colorado for
alcohol-related (i.e., above .08% alcohol content) impaired driving, does not include
testing or screening for additional drugs because they do not receive additional
punishment if the arrestee’s test comes back positive for other substances (RMHIDTA,
2019). There is a potential gap in current treatment protocols because probation
departments and licensed addictions counselors lack a presumptive test for use in licensed
treatment facilities for the detection of whether a counselee is under the influence of
marijuana (RMHIDTA, 2019).
In 2018, violent crime increased 8% in Colorado. Another implication for
addiction counselors was the risk of encountering a forensic population of probationers,
parolees, and those who are involved with violent crime allegations that may involve the
ingestion of marijuana who presents with treatment needs. Since legalization in 2018, the
per-capital violent crime rates in Colorado rose by 7.95% with falling under the category
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of aggravated assault. (Hindi, 2019). Since licensed addiction counselors (LACs) in
Colorado provide services within the criminal justice system, LACs can potentially
expect to encounter more arrested clients in Denver (the largest treatment population). Of
the nation’s largest cities, Denver reported the largest rise in violent crime (Schmelzer,
2019).
Social Costs of Legalized Marijuana
Addiction counselors should be familiar with the effects on the society borne by
Coloradoans because of marijuana-related phenomena. Addiction counselors in Colorado
involved in harm reduction, integrate the current data about overall community outcomes
into their treatment planning when addressing ongoing risks to clients. A major theme of
cannabis use disorder are the associated treatment costs. For example, for every dollar
gained in tax revenue, Coloradoans spent about $4.50 to mitigate the adverse effects of
legalization. Licensed addictions counselors in Colorado deliver the majority of courtordered treatment services related to DUIs (Driving Under the Influence), and in 2016 the
costs of DUI for Coloradoans who tested positive for marijuana totaled nearly 25 million
dollars. However, the largest cost contributor for marijuana-related healthcare results
from high school dropouts (Centennial Institute, 2018).
Legalization of Recreational Marijuana and Physical Trauma.
Researchers detected and reported on physical trauma incidence differences since
the legalization of marijuana in patients admitted to major trauma centers in Colorado
between 2012 and 2015. The implication for addictions counselors was the expectation of
encountering clients at higher risk of physical injury due to increased marijuana
following the commercialization of recreational marijuana (Chung et al., 2019). I sought
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to determine how clinicians experienced this in their lives and how the dynamic affected
the practice of addictions therapeutics.
Juvenile Delinquency in Colorado Schools for Drug and Marijuana Violations.
Colorado police officers who serve as school resource officers (SROs) reported
during the academic school years 2016-2018, 69% of disciplinary incidents in the public
schools related to marijuana violations (vs. 24% other drug violations), 71% of
expulsions, and 77% of law enforcement referrals also related to marijuana violations in
schools (Colorado Department of Education, 2018). This directly correlated with the
increasing use of marijuana among adolescents alongside the attitudes in favor of
marijuana legalization. This disturbing pattern was yet another common forensic
psychology theme I sought to clarify and another relevant theme to develop through the
common field experiences of clinicians. Licensed or certified school counselors and
mental health professionals represent additional integral parts of the allied professional
mental health practice in Colorado public schools. Licensed addiction counselors receive
training and monitoring by the Division of Regulator Agencies (DORA), and more
specifically, the Colorado Department of Human Services (CODHS), Office of
Behavioral Health (OBH).
Brief Summary of Mental Health Indications and Marijuana Use in Colorado.
Discovering the experiences of addictions counselors as they related to mental
health disorders involving marijuana required reaching out to field practitioners. Another
major theme in the literature, documented implications for the treatment of several
behavioral health disorders related to marijuana use. Some of the most relevant findings
concerned adverse mental health effects issued in 2019 by the Colorado Department of
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Public Health and Environment (2019), and the National Institute on Drug Abuse
(NIDA), correlated with other national research findings.
Colorado Marijuana-Related Mental Health Treatment Indices & NIDA
The following relates information regarding the current status of pertinent marijuanarelated issues:
•

Adolescents and young adults who quit marijuana use have a lower risk of
developing cognitive impairment or mental health disorders than those who
continue to use.

•

Daily or near-daily marijuana use by adolescents and young adults is associated
with developing a psychotic disorder such as schizophrenia in adulthood.

•

Marijuana use by adolescents and young adults is strongly associated with
developing psychotic symptoms in adulthood, such as hallucinations, paranoia,
and delusional beliefs.

•

Weekly or more frequent marijuana use by adolescents and young adults is
associated with impaired learning, memory, math, and reading achievement,
even 28 days after last use (Colorado Dept. of Public Health and Environment,
2019).
Several patterns in the research literature correlate with behavioral problems and

marijuana use in Colorado. The correlation provides critical insight into the most at-risk
populations and clues to marijuana use disorder prevention. For example, the earlier
adolescents and young adults quit, the lower the risk of developing cognitive impairment.
Other common patterns involve: (a) the risks of developing a psychotic disorder from
daily or near-daily marijuana use, (b) weekly or frequent use associates with impaired
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learning achievement, (c) marijuana significantly impairs judgment and motor
coordination and the risk of a motor vehicle crash and physical trauma increases after
use, and (d) users exposed to marijuana during development risk long-term or possibly
permanent adverse changes in the brain.
Impacts on Youth
Juvenile Delinquency in Colorado Schools – Drug and Marijuana Violations
Juveniles are the most at-risk population in Colorado for marijuana-related problems.
Researchers associated juvenile delinquency with marijuana use in the literature. In
Colorado, police officers who serve as School Resource Officers (SROs) reported during
academic school years 2016-2018, 69% of disciplinary incidents in the public schools related
to marijuana violations (vs. 24% other drug violations), 71% of expulsions involved
marijuana incidents, and 77% of law enforcement referrals involved marijuana violations in
schools (Colorado Dept. of Education, 2018). These factors correlated with the increasing use
of marijuana among adolescents in addition to attitudes in favor of marijuana legalization.

After Only One or Two Instances of Marijuana (Youth)
In 2019, researchers suggested observable structural brain and cognitive
correlation with just one or two instances of adolescent marijuana use (Orr et al., 2018).
Similarly, one month of abstinence from marijuana improved memory in adolescents
(Schuster, 2018). These findings included implications for treatment planning, building
resiliency, relapse prevention, and sustained recovery.
High School and College Marijuana Treatment Implications
Addiction counselors expect to encounter high schoolers who increasingly use
marijuana edibles, while students who smoke marijuana decrease. For example, in 2017
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students who usually consumed marijuana edibles increased 10% (up from 2% in 2015),
and students dabbling in marijuana increased from about 4% in 2015 to 7.5% in 2017
(Tormohlen et al., 2017). The University of Michigan reported their findings revealing
43% of college students indicated they used marijuana at least once in the past year (the
highest amount since 1983) while 6% of college students surveyed reported using
marijuana 20 or more times in the past month (Stobbe, 2019).
Brief Review of the Medical Implications of Marijuana Use
In my preliminary literature review for this study, I also uncovered dramatic
implications for treatment from emergency medicine intakes and marijuana use. In 2019,
the Colorado Department of Health summarized emergency department discharge
datasets involving marijuana use. Along with other relevant and useful data from
emergency, room discharges inform the practice of addictions counselors as they
encounter trends and differentially make diagnoses (ICD-10 criteria) of marijuana-related
use disorders.
Colorado Dept. of Health ER Discharge Summary
Colorado Marijuana-Related Mental Health Treatment Indices & NIDA
•

Adolescents and young adults who quit marijuana use have a lower risk of
developing cognitive impairment or mental health disorders than those who
continue to use.

•

Daily or near-daily marijuana use by adolescents and young adults is associated

Emergency Room Visits
According to recent research supported by Colorado Department of Public Health
and Environment grant funds, and published in the Annals of Internal Medicine,

29

emergency room visits more commonly accounted for instances of inhaled marijuana use
as opposed to edible marijuana ingestion. However, when emergency department patients
self-report recent ingestion of edible marijuana products, they disclosed severe
psychiatric symptoms along with more emergency room visits than expected (Monte et
al. 2019).
The Center for Behavioral Health Statistics and Quality, Substance Abuse and
Mental Health Services Administration, Treatment Episode Data Set (TEDS) issued its
findings based on administrative data reported by states to TEDS through April 1, 2019,
and the results highly correlated with the previous findings discussed maternal use of
marijuana during pregnancy was associated with negative effects on exposed offspring,
including decreased cognitive function and attention. However, the adverse effects may
not appear until the child entered their adolescent years. The researchers also found
evidence indicating THC passed from the mother’s breast milk potentially affected the
baby.
The most significant source of standards and training for licensed addictions
counselors in Colorado is the Substance Abuse and Mental Health Services
Administration (SAMHSA). SAMSHA recently updated their findings concerning risks
of using marijuana, and this update also highly associated and concurred with the other
major findings (SAMHSA, 2019).
The Paradox of Replacing Opioids with Marijuana
An opinion piece exploring the efficacy of using marijuana in the treatment of
chronic pain and opioid use disorder concluded no convincing evidence of the efficacy of
cannabis in patients, and the irresponsibility of encouraging patients to stop taking
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medications such as methadone, and buprenorphine in favor of an unproven cannabis
treatment (Humphreys & Saitz, 2019). Proponents of medical marijuana suggested the
potential of reducing opioid deaths after its legalization (dataset 1999-2010). However, a
new study published in 2019 extended the time frame through 2017 for associating
medical marijuana laws and opioid deaths, due to the 23% increase in overdose deaths
from 1999 to 2017prior to the introduction of medical marijuana (Shover et al., 2019).
In September of 2019, Randall, an emergency room physician who specializes in
cannabis science and medicine, stated:
The legalization of marijuana has damaged, rather than helped, my home
state. I think the public needs to know that we are not okay… The grand
experiment is not going so well. I don’t think the public is hearing about
this as it should be. The state government has not only ignored scientific
findings of marijuana’s effects to push sales but failed in the regulatory
responsibility it promised would accompany legalization (Lehman, 2019).
In support of these statements, the Pueblo, Colorado-based emergency room
physician noted the increasingly high potency of marijuana products would lead to a
marked increase in medical problems, misguided impressions of marijuana benefits,
increasing numbers of homelessness, and a growing population of chronic, marijuana
dependent users (Lehman, 2019).
Behavioral Health and Marijuana
Endocannabinoid System
Addiction counselors need to be aware that, generally, there is a great diversity of
the role of cannabinoid type 1 CB1) receptors and physical or mental functions. These
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receptors appeared highly concentrated in the hippocampus. basal ganglia, cerebellum,
spinal cord, and peripheral nerves, whereas they found CB2 receptors primarily within
cells in the immune system. The location of CB2 receptors may explain, in part, the
effects of cannabinoids on pain and inflammation (Hill, 2015).
Endocannabinoid systems are critically involved in brain maturation and
development, especially during adolescence and early adulthood. The concern of
adolescent marijuana use focused on the adverse effect on neurogenesis, axon elongation,
neural differentiation and migration, glia formation, and synaptic pruning in the
developing brain (Maccarrone et al., 2014). Stimulating the CB1 receptors by THC,
inhibited neurotransmitter release and the endocannabinoid system, which regulates the
release of neurotransmitters. A critical system in the regulation of memory and other
functions including appetite, memory, mood, pain, sleep, and inflammation, TCH causes
much longer-lasting non-physiological activation of cannabinoid receptors.
Cognition, Motivation, Intoxication, and Addiction
The effects of 9-tetrahydrocannabinol (TCH) critically impact developmental
processes and disrupts the ability to test reality, control impulses, reason, set priorities,
relate to others, and attain goals. Addiction counselors anticipate encountering mixed
messages about using marijuana as an antidepressant or mood stabilizer, instead,
encourage clients to smoke in moderation. However, the limited use of an addictive
substance to treat mental disorders engages an intervention without the proper knowledge
and evidence-based tools. For example, some existing evidence highlights moderate use
of marijuana does not greatly reduce dependence risk (Swift et al., 2009).
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Marijuana’s Intoxicating Effects
Marijuana’s reinforcing effects involve the same mesolimbic dopamine system
that supports the reinforcing properties of other substances of abuse (Bolkow et al.,
2014). There is no scientific support that marijuana is different from other illicit drugs.
Researchers have not documented whether marijuana neural systems overlap with those
of other drugs of abuse.
Brakes Off/Gas Pedal Floorboarded
Both CB1activation and opioid receptor activation “cut the brake cable” of
dopamine release, and this results in the same rapid burst firing of dopamine commonly
known to all drugs of abuse (Cooper & Haney, 2008). An association exists between
acute marijuana intoxication and subjective quickening of euphoria, higher doses for
relaxation, decreased motor activity, and significant calming, intense influx of sensory
information from ordinary stimuli, focus on internal sensations of the body, along with
reality testing (hallucinations, illusions, etc.).It also correlates with impairment of the
executive function (inhibitory) resulting in and hinders shifts in focus, fantasies of power,
and the belief in transcendent insight (Iversen, 2008).
Marijuana and Addiction
Marijuana addiction vitally connects to motivation, scientifically. The question of
marijuana addiction is a well-settled scientific consensus. The mechanisms of action and
addictive phenomena are the same as other addictive disorders (Volkow et al., 2014).
Neurobiology of Addiction
The known neuropsychological domains for marijuana are, a) reward salience (nucleus
accumbens, ventral pallidum, and medial orbitofrontal cortex, b) motivation (outputs
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from the accumbens to the motor cortex, cingulate gyrus, dorsal striatum, and
orbitofrontal cortex, c) implicit and contextual memory (amygdala and hippocampus and
d) control (self-control) (involving the anterior cingulate and prefrontal cortex) (Volkow,
2010). The initial intoxication and bursting dopamine release stamps in the experience as
pleasurable in the amygdala, and these associations fade very slowly and the bursting
euphoria (gas pedal floorboarded) activates the firing in the nucleus accumbens shell,
coloring marijuana experiences very positively and with enhanced value. Following
encounters with marijuana led to a tendency to approach the drug while experiencing a
craving and this process begins before any inhibitory circuits having the chance of
activating (takes control before any reflective or discerning appraisals are possible). The
resulting negative emotional state may prime a stress-induced relapse because the
prefrontal cortex does not function well under stress. Referred to as a euphoric state,
recall leads to chasing the high. Desensitized due to excessive activation of the
mesolimbic dopamine system, the dopamine receptors increasingly reject attempts to
replicate the original experience with marijuana (Volkow et al., 2010). Each use raises
reward thresholds and decreases natural reinforcers of motivation. For example, social
praise, self-efficacy through delayed reinforcement (good grades, rewards from vocation)
insufficiently compares with immediate gratification from marijuana. This is particularly
evident in the moment of craving. Concurrent with negative emotional states (hungry,
angry, lonely, tired, stress, and bored) decreases occur in the tonic firing of dopamine and
the desire to fill the voids. This phasic and unnaturally large bursting of dopamine
circuits leads to additional episodic burst firing of dopamine, which further destabilizes
the reward circuitry of the brain, and the steady tonic firing of the “contented” brain

34

becomes more elusive (homeostatic processes are more difficult to achieve and maintain)
(Volkow et al., 2014).
Potency, Purity, Dosage, and Overdose in Colorado Marijuana Use Pharmacokinetics
Interviews with LACs may reveal very practical concerns related to the
monitoring of client marijuana use in the clinical setting. The pharmacokinetics of
marijuana vary widely depending upon the route of administration. For example, most of
the marijuana dissipates in the smoke, and the estimated bioavailability of smoked THC
researchers estimated at 10% - 25% (Borgelt et al., 2013). The typical euphoric effects
peak in about 30 minutes after ingestion and reach the lower levels in about 3 hours after
consumption. Compared to smoked marijuana, orally ingested THC’s bioavailability is
less because of gastric degradation, and overall, highly variable bioavailability covaries
from one person to another. Therefore, clinicians expect inconsistency in the titration of
edible marijuana products (Borgelt et al., 2013). Ohlsson et al. (1980) summarized the
basic pharmacokinetics of smoked and orally ingested marijuana (Table 1).
Table 1
Pharmacokinetic effects of smoked vs. orally ingested marijuana
Route
Smoked

Dose
13 mg

Oral – Baked 20 mg

Percentage of dose in
blood plasma
8% - 24%

The onset of
euphoric effect
10 minutes

4% - 12%

120-180 minutes

Peak blood
plasma levels
3 minutes
60-120 minutes

in Cookies

The dose-related neurocognitive effects of marijuana interest clinicians because
marijuana remains the most prevalent illicit drug used in Colorado, the United States, as
well as the western hemisphere. Clients should know the persistent effects on the brain.
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In 2001, the first published reports noted the effects of THCs on cognitive function after a
period of abstinence exceeded 12-72 hours (Bolla et al., 2002).
A lack of scientific data persisted concerning any neurocognitive effects of TCH.
Researchers administered a battery of tests to 28-day abstinent heavy marijuana users to
determine whether neurocognitive deficits persist and the decrements related to dosages
(Bolla et al., 2002). They hypothesized cognitive deficits, based on previous studies,
reversed after seven days of abstinence, and correlated with recent cannabis but not
cumulative. They also discovered their ability to observe any lasting decrements in the
heaviest users of marijuana (Bolla et al., 2002). To evaluate the treatment implications of
those who presented with CUDs, very heavy marijuana users experience persistent,
“…negative dose-related effects…on tests measuring verbal and visual memory,
executive functioning, visual perception, psychomotor speed, and manual dexterity”
(Bolla et al., 2002). Interestingly, the results were nonlinear for some tests with a doserelated association between joints per week and cognitive decline duration not strongly
related to performance (Bolla et al., 2002). The most negatively impacted neurocognitive
functions related to memory executive function, and manual dexterity, in which the
hippocampus, prefrontal cortex, and cerebellum generally function.
Potency and Dosage
Colorado officials assessed the physical and pharmacokinetic relationships in
marijuana production and consumption. The original legislation for legalizing and
regulating marijuana did not specifically restrict marijuana concentrates and infused
edibles. Of great concern to clinicians, should be the treatment implications for clients
who present with CUD and changes in the law that now include monitoring, potency,
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purity, and the equivalencies of not only the flower portions of cannabis but their
equivalent (Orens et al., 2015). The volume of cannabis any user can buy or possess at
once (per day) for cannabis flowers is one ounce (28 grams). Medical users can possess
two ounces. Dispensaries must limit the amount of concentrated cannabis to eight grams
total, and 800 mg of THC in any edible product. The legal limit for driving in Colorado is
more than five nanograms of THC (blood plasma) while driving (Orens et al., 2018).
Available scientific data fills a previous gap in knowledge directly affecting
treatment. They measure the comparisons between the marijuana flower, concentrates,
and infused products for physical equivalency in Colorado’s marijuana market yielding a
physical THC equivalency, and a physical production equivalency (Orens et al., 2015).
Butane hash oil (i.e., BHO wax/shatter); carbon dioxide (CO2) oil; ethanol; butter/lipid
(cooking oils), and water are the major product manufacturing techniques for concentrate
and infused product manufacturing. The physical equivalencies reveal that “…between
347 and 413 edibles of 10mg strength can be produced from an ounce of marijuana”
(Orens et al., 2015, p. 6) depending on the production method and solvent type. In other
words, for concentrates the equivalent range of 3.10 and 5.50 grams of concentrate
compares to an ounce of flower marijuana (Orens et al., 2015) because the purpose of
current Colorado equivalency legislation limits purchase transactions or possession of
THC products to a “reasonable dose” of concentrate and other marijuana products, and
knowledge of the pharmacokinetic effects (i.e., the psychoactive experience or the high)
yielded between product types, Orens et al. (2015) felt unable to overstate the importance
of pharmacokinetic equivalencies (see Table 2)
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Table 2
Pharmacokinetic Dosage Equivalency

Buds/Flower

Average THC
Potency
17.1%

Effective
Uptake Ratio
1.00

1 Gram
Equivalent
1 Gram

1 Ounce
Equivalent
1 Ounce

Edibles

N/A

5.71

3 Servings

83 Servings

Concentrates

62.1%

1.00

0.28 Grams

7.72 Grams

Purity & Dosage
Independent private testing laboratories regulate the purity of medical and retail
marijuana in Colorado. Colorado’s licensed testing facilities test recreated products for
potency, contaminants, and homogeneity (Brohl et al., 2015). However, clinicians should
be aware no federal guidelines exist for the testing of medical marijuana for either
potency or contaminants. Because marijuana products derive from plant material, they
are susceptible to contamination from bacteria, molds, fungi, pesticides, heavy metals,
and amateur production techniques that introduce highly toxic substances such as
Vitamin E Acetate. The Centers for Disease Control (CDC) suspected vitamin E acetate
(an oil derived from the vitamin) was an additive found in 23 THC vaping patients who
fell ill or died in 2019 (Krishnasamy et al., 2020). For those seeking treatment for CUD
because of the inherent risks of mortality, or serious bodily injury, understanding the
lived treatment experiences and attitudes of clinicians becomes important information. In
2014, estimates for marijuana supplies and modalities consumed by residents and visitors
totaled approximately 130 metric tons between, or about 54.8 tons per day of dry weigh
marijuana. After accounting for licensed marijuana production supply, about 53.3 tons of
marijuana distribution occurred, “…outside of the regulated framework, and more when
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demand from minors is considered…” (Orens et al., 2018, p. 26). The most recent
estimates of Colorado marijuana reflect 51% of people use it daily, and 16.5% use it 2-3
times per week. Heavy users, who may constitute a higher proportion of clients
presenting with CUD, consume between 1.30 - 1.90 grams per day (Orens et al., 2018).
The known increase risks arise from a lack of purity, variability of untested marijuana
supplied outside regulated frameworks, and the high average dosage of heavy users in
Colorado. Clinicians can now access data and applied it to the formulation of treatment
plans inclusive of strong harm-reduction interventions, including monitoring and testing
of the products clients consume.
Overdose, Injury, and Death from Ingestion of Marijuana
The use of marijuana concentrates continues to escalate. In colloquial terms,
distinguishing the butane extracts (BHO) or “dabbing” from flower cannabis ingestion,
clarifies how the THC derived from this route of administration includes significant
impurities including unpurged butane. This draws attention to the importance of detecting
the heightened risk and carefully appraising clients seeking treatment for CUD. Beyond
the use of butane as a solvent in amateur chemistry production methods, “blasting”
vapors can pool, becoming highly flammable within enclosed spaces and ignite when
exposed to a spark source.
The research into the illicit BHO amateur production represents a clear gap in
information the public can rely upon, because the proportion of data reaching the public
relate to BHO contains broad inconsistencies about the risks, and instead talk about
dabbing as part of a broader, general discussion ignoring the risks. The implications for
treating CUD include clinicians' expectation of increased at-home BHO production,
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despite its consequences, a lack of detailed literature for clinicians to create a response,
and profound deficits of risk awareness. The extant literature reflects a lack of knowledge
concerning dabbing and blasting. Research questions directly related to clinician attitudes
and lived experiences treating CUD need to address BHO “…characteristics, availability,
distribution, rates of amateur production, acute and chronic harms, and the effect of legal
sanctions on production and use” (Al-Zouabi et al., 2018, p. 99). Clinicians should expect
to educate clients that BHO production potentially results in catastrophic events. In
Colorado, a cross-sectional study using data from the American Burn Association’s
National Burn Repository identified the prevalence of hydrocarbon burns via the
University of Colorado Hospital Burn Center and found direct correlations between the
legalization of marijuana in Colorado and an unprecedented increase in hydrocarbon
“flash burns” from BHO production (Al-Zouabi et al., 2018).
While the limit on a single-serving recreational edible THC dose is 10 mg,
multiple-dose recreational edibles packages contain 100mg of THC (the packaged limit
made available in 2014). The treatment implications for CUDs included marijuanaattributed morbidity and mortality, along with the use of mortality surveillance for
guiding preventive efforts in overconsumption in light of Colorado’s first THC-related
death from edibles (Hancock-Allen et al., 2014). A 19-year-old male who ingested a
single cookie jumped off a fourth-floor balcony and died from trauma. A quantitative
toxicology analysis confirmed findings of the presence of cannabinoids – 7.2 ng/mL
delta-9 tetrahydrocannabinol [THC] and 49 ng/ML delta-9 carboxy-THC, (inactive
marijuana metabolite). The decedent was marijuana-naive, with no known history of
ethanol abuse, illicit drug use, nor mental illness. They labeled the ingested cookie “65
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mg THC/6.5 servings (THC, tetrahydrocannabinol, the principal psychoactive in
cannabis).” The label also contained this statement: “This marijuana product has not been
tested for contaminants or potency.” The retail dispensary sales clerk instructed the buyer
and his friend, the decedent, to divide each cookie into sixths, each piece containing
approximately 10 mg of TCH (the serving size in Colorado), and to limit ingestion to one
serving at a time. It is unknown if the sales clerk instructed the buyers how long to wait
between servings. The decedent, not feeling the effects of ingesting only a single piece of
his cookie as directed, consumed the remainder of the cookie (all five servings) 30-60
minutes later. On February 1, 2015, Colorado instituted new packaging and labeling rules
limiting recreational edible marijuana products to no more than 10 mg of THC or clearly
marking each 10-mg serving. They also instituted random testing on batches of
recreational marijuana edibles after this incident. This death was the first reported in
Colorado linked to marijuana that was not associated with polysubstance use since the
approval of recreational marijuana in 2012 (Hancock-Allen et al., 2015). The takeaway
for clinicians highlighted how the delayed effects of THC-infused edibles, multiple
servings consumed in close succession could result in a higher THC concentration, and
therefore greater intoxication, increasing the risks for adverse psychological effects (i.e.,
suicidality or psychotic features), and death. Clinicians should review the cannabis
surveillance literature frequently for emerging trends and associated risks.
Cannabis Use Disorders (CUD) – Risks and Prevalence
The overall prevalence of cannabis use is 3.4% among 12-17 years old’s, 4.4%
among 18-29 years old, and estimated lifetime prevalence = 11.8% in men and 5.4% in
women (in the general population) (Khan et al., 2013). Perhaps the mistaken belief that
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marijuana has a low addictive potential because the ratio of those who develop CUD after
at least one use is much lower than for other drugs (11:1) may be due to social, legal, and
commercial factors and not the result of intrinsic measures of addictive tendencies.
The dose, route of administration, and frequency of use affect the measures of the
addiction potential of marijuana. Hall (2015) suggested 25%-50% of daily users qualify
as dependent and those who continue use after turning18 years old develop addiction
about one-third of the time (Swift et al., 2008).
Removal of Social Constraints
Living alone, major financial problems and impaired control resulting from
marijuana use predict the transition to dependence. With continued use, the brain
becomes less responsive to natural reinforces such as social rewards, employment, and
companionship. This may be due to a gradual social withdrawal from decreased social
interest, and the person becoming less motivated by the pursuit of financial reward and
more directed to using drugs (van der Pol et al., 2013).
Adolescence typically marks critical developmental tasks such as learning selfregulation, accumulating useful experience, acquisition of knowledge for future use in
productivity, and gradually taking on adult roles. These occur in the later development of
the prefrontal cortex. The hallmark of the addiction process points toward expected
rewards that grow from marijuana use over time, overwhelming the brain’s control
circuits. This imbalance develops quickly because adolescents are high reward-oriented
with poorly developed prefrontal circuitry (Casey & Jones, 2010).
Shared environmental factors predominate in those who have an early onset of
marijuana use including low parental supervision, resulting in increased risk-taking. The
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ease of access and perceived risk of use significantly predict marijuana use. Prevention
cues in home environments help children understand marijuana use may reduce
childhood risks as opposed to homes that normalize and approve of using (i.e., homes
that teach risky to use, not immoral to use, lack of parental disapproval, and easy access
variables) (Steen, 2010).
There are some measures such as the transmissible liability index (TLI) that probe
a child’s biobehavioral characteristics such as appetite variability, sleep restlessness,
picking, oppositional/defiant behaviors, and impulsive responding. The TLI associates
with biologically driven behavioral dysregulation and the propensity for social deviance
and a tendency toward developing a substance use disorder (Kirisci et al., 2009).
Marijuana Withdrawal
The answer to whether the body can experience withdrawal with the cessation of
using marijuana is that the science is unequivocal and involves a withdrawal syndrome
including irritability, aggression, anxiety, sleep difficulty, decreased appetite,
restlessness, dysphoria, abdominal pain, shakiness, sweating, fever, chills, and headache
(Budney et al., 2004). Physical and psychological addiction are not technical terms in MJ
addiction and withdrawal. The term pharmacological dependence better describes the
process. MJ withdrawal symptoms negatively correlate with successful substance abuse
treatment outcomes. The greater the functional impairment from MJ withdrawal, the
greater risk of relapse (Allsop et al., 2012).
Medical Marijuana
Indications
Pharmaceutical Formulations of Marijuana
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Of the more than 70 known cannabinoids affecting the endocannabinoid system,
THC is the best known (connected with the psychoactive and euphoric effects), along
with cannabidiol (CBD), which was thought to have anti-inflammatory/anti-epileptic
effects. Purified, tested, marketed, and FDA-approved drugs are dronabinol (Marinol)
and nabilone (Cesamet) both list as schedule II substances having a high potential for
abuse and restricted medical use. Nabiximols (Sativex) is not available in the U.S., but 15
countries approve its use, (including Canada and the United Kingdom. Cannabidiol
(Epidiolex) is in Phase III investigational trials in the U.S.
Monitoring the Clinical Use of Marijuana
A major gap and practical concern of providers of addictions counseling is the
role of drug testing and the interpretation of the tests. The most common drug test (there
is not currently available portable or presumptive test for use in clinics) is a nonpsychoactive marijuana metabolite TCH carboxylic acid (THC-COOH). The length of
time for detection of marijuana in the urine varies widely depending on frequency and
duration of use. Body fat stores marijuana allowing chronic heavy use to have positive
results in urine drug screens up to 67 days after the last ingestion or intake. A naïve user
may have a negative urine drug screen within hours after smoking marijuana. A major
gap in treatment lies in the fact that positive test results for marijuana users do not
definitively determine the date of last use. Infrequent marijuana users take 1-4 hours
before producing a detectable level using urine tests, and the recommended cutoff
concentration of 50 ng/mL for a positive test is a urine immunoassay test. (Heustis,
2007). Blood testing for marijuana correlates closely with time of use and level of
impairment. Recent reviewers of the effects of marijuana on driving skills suggested a
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blood TCH concentration of 205 ng/mL correlated significantly with driving impairment
(Hartman & Heustis, 2013). Clinicians may use saliva tests in the future, and the
advantages would be helpful because the non-invasive detection period correlated with
impairment established for oral secretion tests (Lee et al., 2011).
Efficacy
Pain. Of the 31 controlled trials of various cannabinoids, neuropathic, and chronic
pain, produced mixed results. A majority demonstrated only modest reductions in pain
and several failing to demonstrate any significance between cannabinoids and placebo.
Two revealed increases in pain (Hazekamp & Grotenhermen, 2010; Kowal et al., 2016).
Nausea. Evidence of oral THC formulations as more efficacious than a placebo
for nausea and equivalent to traditional antiemetic medications such as prochlorperazine
exists (Amar, 2006). However, most of the studies for nausea and vomiting occurred
before the availability of serotonin 5HT3 receptor antagonists such as ondansetron
(Zofran) which they considered more effective than phenothiazine antiemetics, which
researchers compared to cannabinoids. There is no evidence supporting using
cannabinoids over modern antiemetic medications, and then only as adjuvant therapy. A
2001 systematic review found cannabinoids more likely caused adverse effects in
chemotherapy-related nausea and vomiting and more effectively treated antiemetics than
several phenothiazines. However, they more likely caused adverse effects, including
dizziness, dysphoria, and hallucinations (Tramer et al., 2001).
Psychosis. Currently, insufficient evidence showing whether the antipsychotic
effects of CBD equated with those of conventional treatments in nonrefractory
schizophrenia (Pushpa-Raja et al., 2014). Heavy marijuana use, high potency of
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consumed marijuana, and a younger age of onset of use worsened disease trajectories and
advanced a first psychotic episode in vulnerable patients by as much as 2-6 years
(Volkow et al., 2014).
Depression and Anxiety. In Norway a 13-year longitudinal survey of 2,033
adolescents associated a significantly increased risk of suicidal ideation and attempts
when subjects are in their 20’s with early onset of marijuana use (Pederson, 2008). A
recent meta-analysis of cannabis and associations with marijuana concluded a dose-effect
exists, pointing to heavy, habitual marijuana use associates with an increased risk of
depression (Lev-Ran et al., 2014). Formulations of high THC: CBD ratios may increase
scores on anxiety scales. Those with low THC: CBD rations often decrease scores on
anxiety scales. CBD appears to modulate brain activity patterns by attenuating responses
in the anterior and posterior cingulate cortex and the amygdala and acts on prefrontal
subcortical pathways via the anterior cingulate and amygdala producing anxiolytic effects
(Crippa et al., 2010). Limits on the generalizability of any positive effects on lowering
anxiety exist because the trials examine only a small number of subjects and a brief
duration of treatment in which healthy subjects enrolled.
Summary of Major Research Findings and Marijuana’s Adverse Effects
Contrary to a common belief that marijuana has few or no adverse effects,
researchers documented adverse effects of short-term, long-term (heavy use), and
long-term or heavy use with initial early onset in adolescence (Croxford, 2003;
Volkow et al., 2014).
Table 3
Adverse Effects of Marijuana Use
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Adverse effects associated with short-term marijuana use
1. Impaired short-term memory and impaired ability to learn and retain
information
2. Impaired motor coordination leading to an increased risk of injuries
3. Altered judgment with a possible increase in high-risk sexual behavior and
increased risk of sexually transmitted infections
4. Paranoia
5. Psychosis
6. Immunosuppression
7.
Adverse effects associated with long-term or heavy marijuana use
1. Addiction: 9.1% of overall users, 17% of those who begin use in adolescence,
and 25%-50% of daily users
2. Chronic bronchitis symptoms
3. Increased risk of psychotic disorders, including schizophrenia, in persons with
a predisposition to such disorders

1.
2.
3.
4.
5.
6.

Adverse effects associated with long-term or heavy marijuana use with
initial use in early adolescence
Altered brain development (changes in size, shape, and density of parts of the
brain, especially the amygdala and nucleus accumbens)
Poor educational attainment with increased likelihood of school dropout
Cognitive impairment/lower IQ
Diminished life satisfaction and achievement
Cardiovascular effects, including tachycardia and postural hypotension
Decreased sperm counts

Note. Source: Croxford 2003; Volkow et al., 2014.
Treatment of Cannabis Use Disorder
From the outset, the literature regarding the treatment of marijuana addiction
tended to follow the same patterns of other illicit drugs. The outcomes of cannabis use
disorder (CUD) based upon long-term studies concluded on average CUD may be less
severe than other illicit drugs. It is clear from the literature CUD involves cases who
experience a severe clinical course leading to very significant health and psychosocial
problems, and those who typically seek treatment for CUD reported nearly daily use for
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more than 10 years and attempted cessation more than six times (Budney et al., 2007).
One major implication for the treatment of CUD since the legalization highlights the
misconception of marijuana as a safe and organic drug that lacks any addictive properties.
The continued belief may block meaningful assessments. A small minority of marijuana
users enter CUD specialty treatment for marijuana problems. Instead, they present to
medical providers with chronic cough and respiratory problems together with anxiety,
fatigue, depression, insomnia, intermittent explosive anger, difficulty concentrating, or
relationship problems. Complicating matters further, marijuana users often present in the
emergency room with physical trauma from accidents or an altered mental state, and
primarily request treatment for alcohol, cocaine, heroin, methamphetamines, or other
substances. They only mention marijuana or nicotine use in passing. About 1 in 10 adult
cannabis users develop dependence, with somewhat higher rates among adolescents. Yet,
many marijuana users simply do not experience any external (noticeable) problems with
use, with about half of daily users becoming dependent (Hall & Pacula, 2003). A major
implication for addictions counselors treating CUD conveys how cannabis addiction
often results in substance abusers exhibiting extreme skill in the ability to dismiss
evidence pointing out how marijuana could be problematic. They witness their friends
who use seemingly do not have any problems regardless of the veracity of these beliefs.
This represents a barrier to treatment, as well as the increased cost of therapy because
early detection of CUD leads to successful treatment and prevention of the disorder
(Compton, 2016).
Screening Tools for CUD
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Addiction counselors should be aware the taxonomy of marijuana remains highly
disparate, regionally covaries considerably, and continues evolving. The implications for
treatment should prompt clinicians to listen closely when marijuana users share the
meaning of various terms. Before legalization in Colorado, marijuana strains typically
contained only 10% TCH. An unpublished study of legal marijuana estimated some
strains contained 30%-90% THC. Licensed addictions counselors should ask about
preferred strains, brands, and visit local dispensaries to enhance their clinical
understanding of the current levels of intake along with the effects on the client. Other
implications for treatment providers include expecting amateur chemists will take a
prominent role in the development and distribution of marijuana products, which will
increasingly become more sophisticated, but effects remaining clinically unknown
(Compton, 2016).
Currently, available valid and reliable screening tools can assist the clinician with
individual assessments and appraisals such as the cannabis use problems identification
test (CUPIT), the severity of dependent scale (SDS), and the cannabis problems
questionnaire (CPQ), which provide more in-depth insights. An adolescent scale is also
obtainable (Compton, 2016). Ideally, the aim of the assessment increases understanding
of motivations, triggers for use, and the barriers to quitting. In other words, they assist
clinicians in determining gains and losses for the marijuana user as well as the function
marijuana initially served. Evaluating a user’s readiness for quitting requires gathering
data regarding what a person likes about using marijuana, paying careful attention to the
differences in what they initially enjoyed and their current level of happiness. The social
context should capture, times of the day, locations, and any other habits. If the various
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contexts create excessive risks for safety and health, immediate targeting them for harm
reduction assures the well-being of the client and the public. Identifying craving triggers
including moods and feelings, as well as people and places that inspire use, provides
valuable information for helping clinicians develop treatment interventions (Compton,
2016).
Evidence-Based Interventions
In Colorado, the approach to CUD treatment is motivational enhancement therapy
(MET), through motivational interviewing (MI). This also serves as the main approach
taught at Liberty University within the Community Care & Counseling, Pastoral Care
cognate (Miller & Rollnick, 2013). Designed to help mobilize internal resources to
resolve ambivalence through conversations, MI and MET do not attempt to guide the
individual stepwise through recovery. Conversational styles or approaches, and the
effectiveness of MET appear to vary with drug type, with primary benefits for cessation
of alcohol use. MET in combination with CBT effectively treats marijuana use disorders
by promoting engagement in the treatment process rather than direct changes resulting in
marijuana use specifically. Clinicians' use of cognitive-behavioral therapy emphasizes
discovering maladaptive behaviors and teaching strategies to challenge, identify, and
correct problematic thinking and behaviors aimed at decreasing use and enhancing selfcontrol. Relapse prevention (RP) demonstrates efficacy for treating a range of cooccurring problems including drug use (McHugh et al., 2010).
Summary
The attitudes and lived experiences of licensed addiction counselors in Colorado
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in the treatment of marijuana disorders directly influence personal and community mental
health. Co-mingling the effects creates difficulties in differentiated its neurobiological,
psychological, and social effects. Since legalization in Colorado for medical and
recreational use, several very negative unpredicted societal effects have emerged and
continue to grow more problematic. Marijuana does not lead to other substance use
disorders inevitably, although cannabis use disorders often develop after initiation of
alcohol and tobacco use. The ongoing and developing treatment implications for
addictions counselors include findings that marijuana use is not the sole cause or cure for
mental health problems. However, a pervasive association with some mental health
disorders continues. Addiction counselors need more awareness of the association
between marijuana use and panic disorders, attention-deficit hyperactivity disorders, and
social anxiety. Using marijuana early in adolescence may increase the risk of anxiety and
depression in adults, along with violence and suicide. However, it is not causally related
to any of the conditions. A dramatic increase in traffic deaths and physical trauma
associated with marijuana use, and its adverse effects on youthful populations is one of
the most surprising developments in Colorado.
The extant professional literature reviewed revealed how marijuana users who
engage in evidence-based psychosocial interventions expect only moderate improvements
in both abstinence and reduction in related symptoms. There is a conspicuous absence of
a 12-step program and biblical counseling efficacy in the literature for problematic
marijuana use or addiction. The recommending or discouraging of the implementation of
faith-based approaches requires conducting additional studies. Other implications for
addictions counselors include a rather disparaging review of clinical trials available for
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standardized treatments concluding they are a little better than no treatment. Thus far the
evidence-based interventions generally do not significantly improve outcomes when
compared with typical interventions. Thus, the research questions for this study probe for
addictions counselors’ experiences and personal attitudes, while pointing to critical gaps
in strategies because “treatment as usual” is not well defined. This dilemma also requires
gathering data from clinical practitioners, including their lived experiences. Compton
(2016) determined, “…the main issue may not be that available interventions are not
effective but rather that the therapeutic action affecting change may be nonspecific.
Structured interventions may serve as convenient vessels to deliver nonspecific
therapeutic benefit by skilled clinicians” (Compton, 2016). The answers to the first
question participants responded to but were not limited to psychosocial interventions or
pharmacotherapeutic agents for reducing marijuana cravings. At the heart of implications
for addictions counselors treating CUD, is the current state of treatment has limited
benefit, despite high relapse rates among those who initially achieve abstinence. I found
the need for more research-based interventions with the hope of disseminating future
effective treatment strategies informed in part by the current and ongoing clinical
experiences of licensed addictions counselors in Colorado. In conducting the literature
review, I identified several protective factors for adolescent marijuana use, and thus
clinicians can seek reduction risk and enhance protective factors in youth as a primary
and necessary treatment goal. Further interaction with clinicians provided this interviewer
with sufficient knowledge to report on the experiences and practices of addictions
counselors in the field who treat cannabis use disorders.
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CHAPTER THREE: METHODS
Overview
Throughout this chapter, I describe the research design and methodology of the study. I
selected a qualitative design to produce new information for licensed addictions
counselors (LACs) in Colorado engaged in community treatment field services with those
diagnosed with cannabis use disorders (CUDs). After the legalization of marijuana in
Colorado for medical and non-medical use, a qualitative inquiry supports the study of the
attitudes and lived experiences of LACs in Colorado and the exploration of the meaning
and implications for addictions counselors and their clients (Heppner et al., 2016).
Wildberger and Katz (2019) reported on the neglect of attitudes and experiences of
addictions counselors who provide treatment for those with substance use disorders
(SUDs), as they present at increased risk of adverse consequences. The relevancy of
qualitative research methods rests in the ability to review the notes and findings from
interviews with clinicians, resulting in a deeper understanding of the interactions
occurring between addictions counselors and those diagnosed with cannabis use
disorders. Qualitative methods offer the promise of informing new counseling methods
and developing a deeper ongoing understanding of treating CUDs from the personal
attitudes and experiences of professional licensed addictions counselors. Ultimately, the
qualitative methods employed in this study through a narrative mode, make the findings
more accessible to practicing clinicians, and a more useful instrument to bridge gaps
between research-based observations and clinical practice (Morrow, 2007).
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Design
Utilizing a qualitative research design enabled the production of new information
for the community of LACs in Colorado following the legalization of marijuana for
medical and non-medical purposes. I focused on the personal attitudes and lived clinical
and personal experiences of those clinicians selected as study participants. The research
questions served as the foundation for the inquiry, and a qualitative approach guided the
methodology for collecting and analyzing data (Merriam, 2009). The clinicians who
participated shared a common interest in treating CUDs or similar experiences relevant to
the research topic.
The nature of qualitative research is interpretive, which encourages the thematic
outcomes emergence as opposed to quantitative approaches, which measure and
configure collected data. I selected a qualitative interpretive approach to focus on gaining
an understanding of participants’ attitudes in treating cannabis use disorders and their
lived experiences as explained by LACs in Colorado. Accomplishing this required
exploring the phenomenon of the treatment of CUDs without regard to previously
existing judgments or the researcher’s previous experiences concerning interventions and
associated implications (Al-Busaidi, 2008).
A phenomenological perception of clinician’s cannabis treatment perspectives
exists regardless of others’ viewpoints. I examined the methods used by clinicians to
reveal how they experience and make sense of their clinical experiences, along with
shaping their worldview, influencing their behavior, and counseling methods (Al-Busaidi,
2008).
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Research Questions
To effectively explore the attitudes of LACs in Colorado after the legalization of
marijuana, I developed the following research questions:
RQ1. What are the attitudes of Licensed Addiction Counselors (LACs) in
Colorado concerning the treatment of Cannabis Use Disorders
(CUDs)?
RQ2. What regulatory, personal, environmental, social, scientific, legal, or
clinical experiences influence the decision-making of LACs who
treat cannabis use disorders in Colorado?
Setting
I collected data by interviewing five qualified LAC volunteers who engage in
private and public in-patient and outpatient clinics, or private practice. The setting
selected for the study reflected the lived experiences of LACs treating cannabis use
disorders in Colorado, and the interpersonal interactions of practitioners, where were
thought of as vitally connected to their expectations, beliefs, goals, feelings, and
ultimately incorporated into their clinical behavioral intentions (Bandura, 1986, 1989,
2001). The LACs social interactions are connected to personal characteristics and their
clinical interactions, which I found influential on their human beliefs, emotional
reactions, expectations, and cognitive abilities. The personal, behavioral, and
environmental factors LACs encounter varied depending on their social status as
behavioral health clinicians. Activating their emotional reactions and decision-making
was operationalized through modeling, education, social persuasion, and clinical
experiences with cannabis use disorder clients (Bandura, 1986).
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Participants
The generic qualitative research method of this study provided an understanding
of the meaning associated with the attitudes and clinical experiences of LACs from their
actual clinical settings (Merriam, 2009). Therefore, a total of five respondents to an open
letter to Colorado LACs took part in this study and met the criteria to share their attitudes
and lived experiences as LACs in Colorado treating cannabis use disorders. All the
participants confirmed having licenses as addictions counselors in Colorado, which I
verified using the list in the Colorado Department of Regulatory Agencies (DORA)
records of approximately 1,935 active LAC licensees.
Procedures
In Colorado, LACs attained varying degrees of experience and training for
intervening with and providing evidence-based treatment to clients who present with
cannabis use disorders. I identified and reported on service delivery issues for LACs
working with cannabis use disorders because clinical issues and concerns surfaced
concerning the application of intervention approaches. The development of treatment
plans, along with ethical and professional opinions, clarified and provided a basis for
consensus about best practices and the need for changes in service delivery. Clinicians
may question their therapeutic role, the scope and efficacy of their intervention
approaches, and their ethical responsibilities when treating cannabis use disorders. There
remains a conspicuous absence in the literature focused on the personal and professional
experiences of clinicians in the delivery of competent services for cannabis use disorders.
Establishing treatment protocols includes clinical experience, as well as education, and
training (Hagedorn, 2009). I utilized semi-structured questions as a guide during the one-
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on-one interviews with clinician-participants. The information served as the conduit for
identifying themes and patterns in their attitudes and lived experiences as they
encountered clients with cannabis-related mental health problems. The interview guide
questions served as the primary research instrument for data collection and ensured
interviews flowed in a functional manner (Merriam, 2009).
Study Interview Questions with Clinician-Participants
The following questions relate to your personal, professional, and clinical lived
experiences treating adults and adolescents who present with marijuana-related mental
health problems.
1. As a clinician what experiences do you have treating marijuana-related mental health
disorders?
2. What guides your clinical decision-making in treating adolescents and adult
cannabis use disorders?
3. Since recreational and medical marijuana was legalized, what personal and
professional experiences are you encountering that are of concern to you?
4. What treatment protocols, strategies, and/or models do you find you use for adults
presenting with marijuana-related mental health disorders?
5. What are your personal thoughts and feelings about the legalization of marijuana for
recreational and medicinal use in Colorado?
6. What are your thoughts and feelings about providing clinical treatment to those with
cannabis use disorders?
7. What do you believe influences and guides your decisions for treatment choices with
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cannabis use disorders?
8. What, if any, regulatory, cultural, social, legal, environmental, scientific, clinical,
and/or geographical influences contribute to your process of deciding on a treatment
plan for adults and adolescents with a cannabis use disorder?
9. What are your thoughts and feelings about the process of deciding on a treatment
plan for clients with cannabis use disorders?
10. Please describe the model of treatment or strategies utilized for cannabis use
disorders?
11. What perceived implications can you share in treatment protocols for cannabis use
disorders?
12. As a clinician who has worked with cannabis use disorders, what treatment
interventions do you believe to be most effective?
13. How do you measure and/or determine treatment interventions as effective with
cannabis use disorders?
14. Please describe any training or education received regarding treatment for cannabis
use disorders?
15. What concerns do you have, if any, regarding the lack of regulating THC dosage
and purity for medical and recreational marijuana users?
16. What concerns, if any, do you have regarding synthetic cannabinoids, and the
treatment of cannabis use disorders?
17. What strategies for prevention, if any, do you utilize in the treatment of cannabis
use disorders?
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18. What programmatic concerns do you have, if any, in the methods and practices of
the Colorado Department of Health for treating cannabis use disorders?
19. Is there anything else you would like to add?
The Researcher’s Role
The role of the researcher in this qualitative research design was to access the feelings
and thoughts of the participants about their lived experiences treating cannabis use
disorders. I accomplished this, in part, by exploring the participant’s personal feelings
while fresh in their minds, or in reliving past experiences. The role of the researcher was
to safeguard the participants and the derived data (Sutton & Austin, 2015). The task of
gaining access to the participants in their natural environment as they encounter clients in
the context of treating CUDs was important in understanding how one’s biases might
influence the outcomes of a study. The qualitative researcher understands interpretivism
does not require strict adherence to objectivity (Clark & Veale, 2018). The researcher’s
role in this study recognized how subjectivity was both inevitable and invaluable because
the qualitative researcher presents assumptions, values, and reasoning for choosing the
topic. and explicit about positionality, which I included in the findings, allows the reader
to encounter the researcher’s findings considering this viewpoint (Clark & Veale, 2018).
Data Collection
The data collection and analysis procedures followed a qualitative methodological
design as I explored clinicians’ lived treatment experiences and factors that contribute to
their decision-making for the selection of therapeutic interventions with clients in
treatment for cannabis use disorders. To accomplish this, I recruited LACs and
intentionally invited them to participate in the study (Creswell, 2009). The derived data
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from semi-structured interviews of five research participants who treat, diagnose, and
provide behavioral health services to clients with CUDs who served as the source of data
for the study.
In conducting semi-structured interviews and the data compiled from interviews
between the researcher and I examined the study participants from a meta-analytic scope
and reduced them to a narrower set of perspectives (Creswell, 2007). The five
participants were voluntarily interviewed in a scheduled 15 to 30-minute open-ended
interview with each digitally recorded and manually transcribed with their consent. The
content from the participants’ interviews revealed patterns or themes characterizing
clinicians’ treatment experiences and associated implications for treating CUDs. I
identified several themes and developed what served as a composite of the findings for
this study. The focus remained on gathering previous clinician attitudes, experiences, or
perspectives.
Data Collection Procedures
I approached members of the Colorado Association of Addiction Professionals
(CAAP) to recruit participants. A print advertisement requested volunteers for the study.
An open letter to CAAP members included a private phone number for prospective
participants to indicate their voluntary interest via secure telecommunication with the
interviewer. I composed a letter of introduction, which was approved along with a
confidentiality agreement the qualified research participants signed. In full compliance
with Liberty University’s IRB requirements, including confidential data collection
settings, and acknowledgment of the content of consent forms, I initiated the recruitment
and interview process. Following confidentiality and anonymity procedures, which
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protect the data, I used numerical encoding and archived any storage of research data for
the required period in a locked secure location (Liberty, 2019).
Data Analysis
Treating CUDs is a new and fast-moving clinical phenomenon in Colorado. This
research started with a critical need for knowledge and guidance to fill numerous gaps
between the social phenomenon of cannabis use, and the subjective clinical experiences
of LACs who treat CUDs. The objectives of the study were therefore subjective and
intended to promote insight and displace confusion regarding obstacles to unified, ethical,
and efficacious treatment modalities by those who treat CUDs (Colorado Dept. of Public
Health and Environment, 2019). The qualified participants received full disclosure of the
intent of this research study and assured confidentiality by maintaining their disclosure
following Liberty University’s IRB procedures. I patterned, coded, and organized the
resulting data by themes, and analyzed the derived themes by way of induction and
comparison. After extracting treatment indices for CUDs I analyzed experiential factors
from the participant’s interviews. The data collection analysis then transitioned to a more
recursive or circular deductive process to facilitate flexibility and adapt to the emerging
findings (Yeh & Inman, 2007). I coded the data received from the qualified participants
along with derived basic demographics.
A thematic analysis guided data ingestion and review both theoretically and
inductively (Caelli, 2003; Corbin & Strauss, 2007; Merriam, 2009). Inductively analyzing
the participating clinicians’ subjective experiences used open coding, organizing, and
categorizing the transcribed interview text, I adopted a continual comparative method of
clustering and content categorizing within each clinician’s interview before analysis
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(Corbin & Strauss, 2007). I uploaded the derived data clusters into the MAXQDA20
software analysis database program to narrow content to themes and subthemes
(Creswell, 2007). This process assisted in predetermining factors influencing and
contributing to clinicians’ attitudes and treatment decisions in respect to CUDs, which I
identified and described theoretically into themes (Braun & Clark, 2006: Merriam, 2009).
Any derived themes represented a narratively expressed result, which helped in
identifying key characteristics of a similar patterned majority of textual interview themes
of the lived experiences of treating CUDs by field practitioners. These methods had a
shared goal that sought to uncover, explore, and describe the study phenomenon, as
opposed to empirically test, predict, or merely hypothesize (Merriam, 2009).
Trustworthiness
I used multiple methods to achieve the trustworthiness of the data analysis
process, resulting in a clear rendering of the study participants’ clinical experiences in
treating CUDs in Colorado since legalization. The techniques used to develop indicia
of trustworthiness in the study included credibility, dependability, and conformability
or transferability. The methods achieved the goal of validating the collected data for its
trustworthiness, which allowed the researcher to interpret the intentions of participants’
responses more reliably (Williams & Morrow, 2009).
Credibility
Validating the credibility of the study increased the likelihood the participants
reported their lived clinical experiences in a manner that correlates with the reality of
their actual experiences (Rolfe, 2006). Credibility is often equated with the internal
validity of a quantitative study, and a credible study, “establish[es] a match between the
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constructed realities of the respondents and those realities represented by the
research(s)” (Sinkovics et al., 2008, p. 699). To ensure the credibility of the study, I
employed quality assurance and control methods, which included epoche, triangulation,
and member checks.
Epoche. Using bracketing helped me reflect upon my considerable knowledge
and experience in professional counseling and isolate my thoughts and feelings
throughout the dissertation classwork, interactions with my peers, and journaling in
the discussion area within the online course shell (Hamill & Sinclair, 2010). The
process of bracketing allows the researcher to acquire new information in one’s
discipline without assuming the outcomes of the investigation (Moustakas, 1994). I
maintained a mindful and disciplined approach about my past experiences and ideas
concerning LACs experiences with CUDs and applied other trustworthiness
techniques (triangulation, member checks, peer/expert review) to ensure I achieved the
separation.
Triangulation. The utilization of multiple methods of data collection
(interviews, journals, and focus groups) provided a corroborating effect from the
collected data (Creswell, 2013; Shenton, 2004). Utilizing “a diversity of informants”
(Shenton, 2004, p. 66) through various means helps to create a “rich picture of the
attitudes, needs or behavior of those under scrutiny” (Shenton, 2004, p. 66).
Triangulation does not “check the validity of the data” itself but validates the
researcher’s interpretations because of the use of “multiple data sources” (Hadi &
Closs, 2016, p. 643).
Member Checks. I asked participants to validate transcripts of interviews
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and my analysis of all the data. This assisted in the correction of any errors in
transcription from the audio recordings. Participants verified the content of their
words, and “offer reasons for particular patterns observed by the researcher”
(Shenton, 2004, p. 68).
Peer/Expert Review. I took advantage of numerous opportunities in the
dissertation formulation process to ask professors and colleagues to provide a peer
review and their unbiased perspective of the methodological approach and
theoretical framework for this study. This provided the necessary review to
“challenge assumptions … refine methods, [and] strengthen … arguments” (Shenton,
2004, p.67). Peer review is appropriate and “keeps the researcher honest” (Creswell,
2013, p. 251) through scrutiny and evaluation of procedures and findings to produce
an accurate portrayal of the participant’s experience with treating CUDs.
Transferability
Another measure of trustworthiness is the applicability of a study in other
contexts as a measure of external validity (Connelly, 2016; Hadi & Closs, 2016;
Williams & Morrow, 2009). This qualitative study focused on the participants and their
perceptions and stories to generalize the results in other settings, rather than on a
statistical basis. I completed this step to “focus on the informants and their story without
saying this is everyone’s story” (Connelly, 2016, p. 436). The current study relied on
openness by clear articulation of study methods (Connelly, 2016).
Quantitative studies strive for generalizability so repetition of the study’s
methods in other settings produces similar results. In contrast, qualitative studies,
“focus on the informants and their story without saying this is everyone’s story”
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(Connelly, 2016, p. 436). Rather than generalizability on a statistical basis, qualitative
researchers should be open about their methods and analysis (Connelly, 2016). In the
current study, I achieved this openness by clearly articulating my methods.
Clear Articulation of Methods. The nature of qualitative inquiries allows
other researchers to reproduce the procedures but “not necessarily the participant
sample or findings” (Williams & Morrow, 2009, p. 578). While the nature of
qualitative research may limit the probability of producing similar findings, this study
described the methodology openly to allow seasoned researchers to replicate the
findings from having used sound methodology in data collection and analysis (Shenton,
2004; Williams & Morrow, 2009).
Ethical Considerations
Ethical considerations for this study included privacy, security of the recorded interviews
and text transcriptions, and the possibility of emotional or psychological discomfort
experienced by the participants. The use of pseudonyms for all participants to disguise
their identities, limiting demographic information to the study’s qualifications (18 years
or older, an LAC, and experience treating CUDs), as well as using data encryption and
multi-factor logins to lock down both the audio and written transcripts of the participants
addressed and managed any questions regarding ethical conduct. I informed the
participants of the opportunity to opt-out at any time, without penalty, and stated the
ability in the informed consent in writing and verbally during the interviews.
Summary
I expected the results of this qualitative study to produce missing knowledge,
insight, understanding, and meaning of the emerging attitudes and lived experiences of
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addictions counselors in Colorado after the legalization of marijuana for medical and
non-medical use. One major supposition for this study was the clinical experiences of
addictions counselors in Colorado drive the decision-making for client interventions and
needs. Licensed addictions counselors are subject-matter experts who presently confront
and treat ever-widening substance abuse problems, as well as assess and diagnose
cannabis use disorders. Numerous themes emerged from the sampling of clinicians
including ongoing personal attitudes, social, legal, scientific, regulatory, environmental,
barriers to research, along with pharmacological nuances (i.e., dosage and purity), and a
myriad of other new non-linear dynamics related to the lived experiences of clinicians in
Colorado. The pace of changes in CUD treatment is quickening, making it difficult to
carve out certainties and best practices. This study, informed in part by a review of the
professional literature, will provide an added context from the attitudes, opinions, and
experiences of LACs. I considered the extent to which interpersonal, behavioral, legal,
political, and environmental influences affect addictions counselors, to identify the
attitudes and lived experiences of addictions counselors who treat CUDs in outpatient
mental health programs and individual therapeutic settings in Colorado.
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CHAPTER FOUR: FINDINGS
Overview
The purpose of this qualitative study was to produce new information from
licensed addictions counselors in Colorado engaged in community treatment field
services for cannabis use disorders (CUDs). Since the legalization of marijuana in
Colorado for medical and non-medical use, this qualitative inquiry allowed for the study
of the attitudes and lived experiences of LACs in Colorado. I also explored the meaning
and implications for addictions counselors and their clients. In conducting semistructured phone interviews with the participants, I recorded the interviews and generated
verbatim transcripts from the audio recordings. Thematic analysis guided the data
ingestion and reviewed the results both theoretically and inductively using open coding,
organizing, and categorizing the transcribed text. I adapted a continual comparative
method for clustering and content categorization within each clinician’s interview before
analysis. Following this, I uploaded the derived data clusters into the MAXQDA20
qualitative research analysis database program to narrow content into themes and
subthemes. Predeterminate factors influence and contribute to clinicians’ attitudes and
treatment decisions in treating CUDs, which I identified and described theoretically as
themes. The themes represented in the narratively expressed results assisted in identifying
similarly patterned themes of the lived experiences of LACs treating CUDs.
The research questions guiding this study were:
RQ1. What are the attitudes of Licensed Addiction Counselors (LACs) in
Colorado concerning the treatment of Cannabis Use Disorders
(CUDs)?
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RQ2. What regulatory, personal, environmental, social, scientific, legal, or
clinical experiences influence the decision-making of LACs who
treat cannabis use disorders in Colorado?
Participants
A total of five clinicians responded to the open letter to Colorado LACs who took part in
this study and met the criteria to share their attitudes and lived experiences as LACs in
Colorado treating CUDs. I confirmed all the participants as LACs in Colorado listed in
the Colorado Department of Regulatory Agencies (DORA) records of approximately
1,935 active LAC licensees. I briefly introduce the participating LACs and provide their
histories below using pseudonyms to protect their identities and verified each met the
study criteria relating to their experience treating CUDs in Colorado.
Participant Backgrounds
LAC#1
LAC#1 worked in substance abuse treatment for the last 12 years, which included
both adults and adolescents. LAC#1 has extensive experience with substance use in the
forensic population and community-based therapeutic work. LAC#1 is an addiction
counselor trainer, collegiate faculty, and doctoral student. LAC#1 is also an expert
addiction counselor, a licensed professional counselor, and a nationally certified
adolescent addictions counselor. LAC#1 is also an adjunct professor and teaches as an
OBH approved Certified Addictions Counselor Trainer, providing clinical supervision
and consultation to other professionals in the mental health field. LAC#1’s experience
would potentially epitomize the ability to relate the attitudes and experiences of a LAC
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who treats cannabis use disorders and generalizable addictions work. LAC#1
concurrently identified a major theme in addictions stating,
1 stated that in her clinical decision making, which is the same for CUDs and
substance use disorders in general, “…I look at the use of the substance as a
deeper driving issue…to be deeper in terms of specific problems or comorbidity
like trauma. This is probably the biggest, yeah trauma plays one of the biggest
roles in comorbidity; could be physical, emotional, or attachment trauma.
LAC#2
LAC#2 has worked in treating cannabis use disorders for the past 16 years and is a
treatment provider for the State of Colorado Department of Corrections. LAC#2
primarily works with adults in prison along with probation populations. LAC#2 is a very
experienced clinician who is a treatment provider for the courts and mainly works with
clients and probation departments for court-ordered clients receiving treatment for
cannabis problems, and other substance abuse issues. LAC#2 also has a diversity of
experience in treating parole clients who are trying to re-enter society after being released
from prison said, “…so people come to see me, and they’ll say yes, I want to work on my
substance use disorder, I’m going to give up alcohol, but I’m still going to use pot.”
“…they may not miss the meth or the cocaine or whatever, but they really miss the
marijuana, and I don’t know why, but that’s the one that they want to come back to.”
LAC#3
LAC#3 has 15 years of experience as a clinician in substance use disorder treatment.
They work in a large university-based psychiatric treatment center that specializes in the
treatment of substance use disorders including cannabis use disorders. LAC#3’s
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organization runs three certified opioid treatment facilities and routinely treats cannabis
use disorders in the context of polysubstance abuse. It is the largest opioid treatment
program in Colorado that administers methadone or other opiate substitutes as part of
facilitating recovery. LAC#3 revealed a highly relevant phenomenon in this study. While
administering marijuana to those in OPT methadone programs they identified an
association with shorter stays because the treatment reduces cravings for opiates.
LAC#3’s access to medical and psychiatric providers along with numerous rigorous
studies of cannabis effects proved helpful in identifying new information and experiences
in the treatment of CUDs such as,
…so, in the state of Colorado, we are not required to test for cannabis, so in many
of the OTPs, this is not actually done. And the state of Colorado did not consider
cannabis positive in a urinalysis result to be something of an infraction, so it
doesn't necessarily restrict take-home medication for methods. However, our
organization has made the determination that people with more disorder are at
higher risk for diversion or unsafe behaviors with regard to methadone take
homes and so have determined to limit the number of take-home bottles that a
patient can receive if they meet criteria for moderate or severe according to the
DSM 5.
LAC#4
Treating polysubstance use disorders, or people using multiple substances,
LAC#4’z 15-year career includes experience treating cannabis use disorders. LAC#4
observed
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Yeah, so what's interesting is as I treat people with like polysubstance disorders or
people that are using multiple substances. I find that that as far as that cannabis
tends to fall lower on that list, so people come in to see me, .and they'll say yes, I
want to work on my substance use disorder, I'm going to give up alcohol, but I'm
still going to use pot.
LAC#4 was able to relate struggles with legalization in the context of their family
history,
So, I struggle with that, have had my own brother who struggled with marijuana
use from an early age and saw how it kind of really stunted his growth and
decreased motivation and all the things we think of with marijuana use. Uhm, I've
also seen and having a young kid. Well not young anymore. They're teenagers
like 20s now. Uhm, just knowing how to navigate. How do I navigate that now
that it is legal like it's just a harder conversation to have.
LAC#5
Employed in the behavioral health and addictions field for about 8 years LAC#5
started as a clinical assistant/drug-monitoring technician at a large in-patient drug and
alcohol facility. LAC#5 worked their way up into a therapist role in DUI services for
court-ordered participants in treatment, as well as intensive outpatient programs. LAC#5
also worked in jail, school, and psychiatric hospital settings. The latter settings provided
similar challenges to those he experienced while providing DUI services LAC#5, the
least experienced of the participants, worked five years less than the average number of
years’ experience among the other LAC’s participating in the current study. However, in
the eight years of LAC#5 involvement in the behavioral health and addictions field, they
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gained a wealth of knowledge and experience. The DUI referrals offered the greatest
challenge since many of the clients resisted the court’s insistence on treatment.
Especially relevant to the current study, LAC#5 also worked with those who have
used marijuana and noted clients often referred for one reason, reveal marijuana as an
underlying cause. LAC#5 reported:
“…in which marijuana was actually a major factor in being just unmanageable
and essentially just ruining a person’s life, and out of those there have been a
couple of occasions where the patient was very aware and very vocal that
marijuana was perceived as lethal. Sure. On a couple of occasions, the client
definitely perceived that it was killing them. It was certainly a part of the puzzle
that was creating dysfunction, in many cases even physically.
Results of Analysis
This section details the analysis conducted following hierarchical, linear, and
structured qualitative methods of entering and coding the participants’ interrelated
experiences, by multiple descriptors, and interpreting the derived themes (Corbin &
Strauss, 2007). To address the research questions driving the study, I developed interview
questions with the intention of revealing answers to the research questions (see Appendix
C). The decision to use a qualitative methodology, guided by reciprocal determinism,
resulted in a useful, flexible, and recursive analysis. The derived six themes provided
straightforward and clear contexts for answering the research questions to understand
how LACs experience treating CUDs in Colorado since the legalization of cannabis. The
narrative includes a “textual description” of answers to the research questions follows the
thematic descriptions and listings (Moustakas, 1994, p. 120).

72

Theme Development
I transcribed the recorded interviews into verbatim text transcripts (voice-to-text)
and conducted a diligent search for repeated words and phrases offered by the
participants, via the MAXQDA20 database software functions. Analyzing the data
included performing database keyword index searches, Boolean searches, as well as
color-coding and cross-matching of the participant’s responses to the semi-structured
guided interview questions. After color-coding and bookmarking commonly used words
and phrases, I organized the color-coded themes based on their similarity, repetition,
which resulted in data clusters, or words and phrases placed together in parallel
(Moustakas, 1994). The theorist called this action, “redaction, reduction, and
elimination” (Moustakas, 1994, p. 120). The repeated words and phrases arranged in
data clusters facilitated the development of specific themes, which I validated based on
the totality of the recorded data (Moustakas, 1994).
I used the derived themes produced from the coded patterns that appeared most
often to report the findings. Analysis of the data produced six themes. The themes were
a) LAC clinical experiences that inform treating CUDs, b) LAC clinical decision making,
c) LAC treatment models, theories, and interventions for CUDs, d) LAC CUDs treatment
implications since the legalization of marijuana, e) LAC concerns regarding TCH dosage,
purity, and safety, and f) LAC strategies for prevention.
Discussion of Findings in Relation to the Theoretical Framework
I relied on the theoretical framework for this study, Bandura’s
conceptualization of reciprocal determinism, which he derived from social cognitive
theory. It essentially posits the causation of social phenomenon is rooted in one’s

73

personal, environmental, and behavioral influences (Bandura, 1986). The theoretical
literature does not contain the application of this theory specifically to clinicians’
experiences as LACs in Colorado treating CUDs, therefore several assumptions
guided the study drawn from reciprocal determinism. For example, one
presupposition of this study indicated the bases of participants' projected clinical
cognitive decision-making rested on personal and environmental factors. These
were a strong impetus and motivators for treating clients with CUDs. Therefore,
social learning factors gleaned from the participants’ data were analogous to words,
statements, and shared stories from the recorded study interviews (reciprocally
determined). The basic idea of reciprocal determinism is that stimulus events are
transformed into individual behaviors (Williams et al., 2010).
Personal Factors
Bandura (1989) found reciprocal interactions between thoughts, affect, and
behaviors. Personal factors include one’s affective, interpersonal, and cognitive
perceptions. This study incorporated examples of how participants related their
personal and professional histories treating CUDs. For example, one participant,
reflecting on the dosage, purity, and potency of cannabis shared how their concerns
escalate about the safety of cannabis after reading a story about children ingesting a
THC edible mistaking it for candy.
Environmental Factors
Bandura (2006) concluded environmental influences associate with
interactions between personal characteristics and environmental influences and
social influences convey information affecting human beliefs, expectations,
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emotional reactivity, and relative cognitive competency. Physical attributes such as
gender, culture, age, and perceived attractiveness, can prompt a variety of reactions
related to a person’s social status and role, and these environmental factors coupled
with “status” then activates emotional reactivity through modeling, instruction, and
social persuasion (Bandura, 1986). The theorist thought social status related to an
individual’s actions (Bandura, 1989.
As participants reflected on their experiences and field observations with
clients with CUD, they revealed the influences of multiple environmental factors in
clinical decision-making and treatment choices. One example of the persuasive
nature of environmental factors on LACs was their considerable training, modeling,
instruction, and social persuasion embedded in master’s level academic preparation,
and required advanced training. LACs take mandated state-certified classes (from
LAC trainers) in the areas of the nature of actions, two courses in
psychopharmacology, two courses in motivational interviewing (including the
mandatory taping of a mock session and peer feedback), infectious diseases, history
of addictions treatment, and two supervision courses. Another example of
environmental factors discernable from the development of the participants’
philosophy of the legalization of marijuana, involved conversations with their
family members. For example, LAC#4 shared:
So, I struggle with that, have had my own brother who struggled with
marijuana use from an early age and saw how it kind of really stunted his
growth and decreased motivation and all the things we think of with
marijuana use. Uhm, I've also seen and having a young kid. Well not young
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anymore. They're teenagers like 20s now. Uhm, just knowing how to
navigate. How do I navigate that now that it is legal like it's just? It's a
harder conversation to have. It’s not something that I would want my kids to
be partaking in and just from my personal experience and what I've seen
throughout my family and harder conversation to say, yeah, I'm OK. with
you having a beer, but for you to smoke pot seems more uncomfortable, so
uhm yeah, I think it's a much difficult, much more difficult conversation.
Behavioral Factors
Within reciprocal determinism, behavioral factors heavily affect environmental
influences and reciprocally alter them, (Bandura, 1989). I conducted the study under the
presupposition within reciprocal determinism, people’s bi-directional environmental
factors exert influence in a way people become both producers and by-products of their
environments. People’s interactions shape their behavioral intentions from their thinking,
values, beliefs, expectations, and self-perceptions (Bandura, 1986, 1989, 2001). I
assessed behavioral influences from the participants’ statements concerning their
perceptions of treatment strategies “directionally” and deduced through the dynamic
environmental factors experiences working with cannabis use disorder clients. All the
participants agreed about the use of assessment procedures and protocols for evaluating
clients as by-products of their environments and related numerous instances of training
and personal influences that affected their clinical decision-making processes and
outcomes.
Discussion of Findings in Relation to the Literature Review and Developed Themes
Theme 1: LAC Clinical Experiences that Inform Treating CUDs
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The LAC clinical experiences compiled from their responses to the guided
interview questions revealed their adeptness in multi-modal treatment practices (Primm et
al., 1999). The LAC participants also used their intuition drawn from the consequences
they observe treating CUDs. They garnered unique cause and effect relationships in
absence of current and specific guidelines and standards for treating CUDs once obscured
by a lack of scientific findings of the full extent of consequences when the body and
brains exposure to increasingly higher concentrations of THC. The LAC participants
unanimously identified their default approach as a compassionate, nonjudgmental clientcentered approach, free of any pre-conditions including abstinence, and concurred
regarding ethical treatment practices when intervening with CUDs use DSM, which
controls and defines disorders. The DSM prescribes the need for a significant impairment
to functioning, and all the LAC participants rejected the use of punishing, guilting or
shaming clients with CUDs. LAC participants unanimously favor legalization because
they perceived this leads to better treatment outcomes.
Specifically, LAC#2 reported, “Thing is I am now seeing actual physical
withdrawal other than just psychological withdrawal. It’s not a severe thing, but
irritability will be increased, sleep will be disrupted, appetite will be lessened. But those
all go away in a couple of weeks.” LAC#2 attributed this in part to clinical experience of
increases in THC potency and concentration. They shared, “Cannabis used to come in at
between 3% and maybe 5% THC, and anymore it’s pushing 30%, and that’s not dealing
with the concentrates that are out there.”
LAC#5 stated their clinical experience included a very small number of clients
(less than five cases over 7-8 years), purporting:
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… marijuana was actually a major factor in being just unmanageable and
essentially just ruining a person’s life, and out of those there have been a couple
of occasions where the patient was very aware and very vocal that marijuana was
perceived as lethal. Sure. On a couple of occasions, the client definitely perceived
that it was killing them. It was certainly a part of the puzzle that was creating
dysfunction, in many cases even physically. More specifically, eating habits and
appetite. I’ve had clients experience needing marijuana in order to eat and when
they attempted to cease use of the substance they struggled with eating, and other
basic needs sometimes too. Also, client’s marijuana use leading to them
experiencing an increase in anxiety or depressive symptoms to the point of
suicidality or first-time occurrence of psychosis. Erratic and unsafe behaviors
often resulting.
The LAC participants were unanimous in their belief that clients tended to
overlook all evidence of THC as addictive. LAC#5 stated, “…people don’t have all the
information, don’t know the risks, particularly the long-term risks…they’re willing to
overlook all other evidence that points to negative implications.” LAC#3 commented:
…marijuana is addictive and there are a lot of people that use marijuana that don’t
think it is. And yet when you read the diagnostic criteria in the DSM for CUD it is
clearly addictive. It has the potential for addiction and overdose. And Prof.
Emeritus Dr. Tom Crowley at the University of Colorado Dept. of Psychiatry, did
a study a few years ago about psychosis and a correlation of marijuana use and
psychosis, and there should be some type of warning in Colorado, and do a better
job of packaging as well in terms of ingredients and warning as well.
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The LACs also agreed that clients do not see CUD as a disorder, and CUD
occurs most often in the context of polysubstance abuse. LAC#3 remarked, “ It's pretty
rare these days to find somebody who's just solely using cannabis and only meets criteria
for cannabis use disorder. You know generally, we have, you know, polysubstance
users.” LAC#4 observed:
Yeah, so what's interesting is as I treat people with like polysubstance disorders or
people that are using multiple substances. I find that that as far as that cannabis
tends to fall lower on that list, so people come in to see me, .and they'll say yes, I
want to work on my substance use disorder, I'm going to give up alcohol, but I'm
still going to use pot.
LAC#2 informed by their work with the forensic population:
“…for whatever reason, it's the one that they miss and a lot of times I'm an
approved treatment provider for Department of Corrections and have been for a
long time and a lot of times people have been incarcerated for substance-related
issues, once they have been released from prison they like they miss the
marijuana. They may not miss the meth or the cocaine or whatever, but they really
miss the marijuana, and I don't know why, but that's the one that they want to
come back to.” LAC#3 observed in the context of her very large OTP treatment
population, “…so in the state of Colorado we are not required to test for cannabis,
so in many of the OTPs this is not actually done. And the state of Colorado did
not consider cannabis positive in a urinalysis result to be something of an
infraction, so it doesn't necessarily restrict take-home medication for methods.
However, our organization has made the determination that people with more
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disorder are at higher risk for diversion or unsafe behaviors with regard to
methadone take homes and so have determined to limit the number of take-home
bottles that a patient can receive if they meet criteria for moderate or severe
according to the DSM 5.
Paradoxically, LAC#3 found in their clinical experience that:
…there are shorter lengths of stay for people using marijuana when receiving
methadone treatment…it’s helpful to be on medication at least for opioid use
disorder or alcohol use disorder, and then we find that in a lot of cases that
cravings and the number of days used are decreased.
Theme 2: LAC Clinical Decision Making
The LAC participants qualified their clinical decision making and practice in
treating CUDs with all LACs identifying the DSM diagnostic criteria for an accurate
differential diagnosis, standardized assessment, well-researched and established standards
(e.g., SAMSHA), together with adequate supervision, as vital to their clinical treatment
decisions. LAC#3 related their treatment center:
…absolutely relies heavily on the DSM5, and we also use an assessment tool
called the Global Appraisal for Individual Needs, which is also known as the
“GAIN Engine.” Historically we used the Addiction Severity Index Light Version
and had special permission to use it from Dr. McLellan, but what we found was
that the ASI wasn’t substantial enough for our needs for reimbursement frankly,
so we switched over to the GAIN Engine, and it’s a much more comprehensive
assessment so we generally use that.
LAC#5 related that when asked about what guides clinical decisions in treatment CUD:

80

Yeah, the first things that come to mind are the diagnostic criteria of cannabis use
disorder in the DSM, and quite a bit of background working with the DSM
criteria and determining the level of care options are a pretty big part of my
practice.
LAC#5 emphasized, “You really need to determine whether you really have a cannabis
issue that needs to be addressed.”
Two other areas of special focus with respect to clinical decision-making surfaced
within this theme. The first is the necessity for clinicians to assess neuropsychological
and neurophysiological processes in all substance abuse populations and provide clients
with psychoeducation in this area to help them understand the effects of THC in the
brain, and as LAC#5 put it, “…helping them understand how far along we are with
understanding a general kind of framework as far as how compulsive substance abuse
creates disordered brain functioning.”
LACs were also particularly united in their regard for how a client’s history of
trauma informs their decision-making in substance abuse populations, including CUDs.
LAC#2 remarked, “…I work a lot with trauma survivors for 16 years and I find a lot of
substance use disorders are rooted in a history of trauma.” LAC#1 stated that in their
clinical decision making, which is the same for CUDs and substance use disorders in
general, “…I look at the use of the substance as a deeper driving issue…to be deeper in
terms of specific problems or comorbidity like trauma. This is probably the biggest, yeah
trauma plays one of the biggest roles in comorbidity; could be physical, emotional, or
attachment trauma.”
Theme 3: LAC Treatment Models, Theories, and Interventions for CUDs
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The five participants followed a cognitive-behavioral approach primarily
informed by a harm-reduction model, contingency management, disease model, or clientcentered focus with repeated words from the participants that, “meet the client where
they’re at” with LAC#2 concluding:
…and if they don’t think that there’s an issue to be addressed you’re not going to
make any progress. I like to go back and take a look at the reasons for using, and
what we find is one of two issues or both. It’s either that we are turning on a
positive or we’re turning off a negative. Turning on a positive means like the buzz
for hanging out with my friends and having a good time. Turning off a negative
cognitively is hey I don’t want to feel this way anymore and reflected in a trauma
history.
LAC#1 argued:
…the hard part of the moral model is the construction of the disorder itself and it
still influences treatment and treatment conversations. Rather than saying let’s get
inquisitive and try to understand why people want to get high, we instead say that
it's just bad, and we, therefore, have to regulate and control the substance because
people can't use it safely when really the science would suggest that 90% of
people who use don't have a problem, so the science isn't validating in a lot of
ways. The layman's construction and really continually influences, bidirectionally, the moral model, and the moral conceptualization-we still punish
people, we still kick them out of treatment, we still try to just control the
substance, that’s the whole “abstinence” construct too.

82

The participants, without exception, agreed that cannabis about decriminalizing
because, as LAC#1 framed it:
… this still acknowledges that abused substances are dangerous and also
acknowledge that people will still use them, but that we would treat them rather
than incarcerate them. Criminalization produces the narrative to influence the lens
through which the substance is based.
The participants in this study all utilize motivational interviewing techniques to
facilitate change talk, resolve ambivalence, and find this to be the prime model and
intervention for CUDs that helps move clients through the stages of change (Miller &
Rollnick, 2013). LAC#2’s narrative summarized the participants preferred model of
intervention, in that:
clinicians should understand that clients need to be ready for treatment, with the
best results in treatment outcomes occurring if the client is doing it for themself.
External influences have an effect on treatment outcomes, but lasting change is
associated with being motivated to benefit oneself. In other words, it has to move
from a punitive focus to an internal locus of control.
Theme 4: LAC CUDs Treatment Implications Since Legalization of Marijuana
The participants concurred with the need for removal of cannabis as a Schedule I
controlled substance and decriminalized. LAC#5 put it this way:
I would like to see the Feds get off of their conservative high horse and get
cannabis off the Schedule I classifications so that we can get vital research done.
You’re not going to get any federal money for research as long as it’s a Schedule
I. So, if we can move the needle down a notch and some funding and research
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done, that would be very, very helpful. There are dozens of cannabinoids that we
don’t know what they really do. Anecdotally, I have clients that say they get
significant benefits from CBD, and it will help with sleep, pain, and a lot of
different conditions. It would be nice to get some actual evidence of the use of
CBD to help these certain issues. It would also be helpful to do the same thing
with THC. We need to get the research done, we know more about almost every
other substance and the mechanics of how they work than we do cannabis.
LAC#1 summarized the primary treatment implications since legalization stating:
I think when we can better science and really understand what’s unique about
those who struggle we have a greater opportunity to create effective treatment
options. But right now, they’re trying to treat with incomplete science means
we’re shooting darts in the dark. We’re facilitating the narrative that the substance
should not have an application when really every psychoactive substance is just a
chemical compound and it’s neither moral nor immoral.
Theme 5: LAC Concerns About THC Effects, Medical Efficacy, Dosage, Purity, and
Safety
The LACs in this study expressed concern about a lack of research-based findings
of the effects of THH, and they generally did not have any confidence in the medical
efficacy of THC based upon research. Collectively, they described their concerns about
the steadily rising potency of TCH and the potential consequences of use worsening. This
runs parallel to and concurrent with deep concerns by the participants about synthetic
cannabinoids as well.
LAC#3 stated:
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Well, I think that first and foremost just how I would, how I like to approach
things is with policy and some type of organization and I think the field cannabis
is grossly under-organized and doesn't have enough oversight. So, I spoke with
somebody a couple of years ago who happened to be a member of the health
inspectors’ team and their focus was cannabis dispensaries and what they said was
if it's a liquid, they treat it like olive oil, and it's just very bizarre because there’s
just not any rules in place. For example, when you have a serving of cereal with
milk you have some nutritional facts and labels that are heavily regulated by the
FDA, and these organizations have to follow those rules and identify how many
nutrients are in a serving. And that the servings are going to be equal in terms of
these nutrients, and so that a person can confidently, you know, have one serving
and then another serving, and know that the nutrients are going to be the same.
But in marijuana, for example, you know you have a cookie that has 100
milligrams of THC and there are 10 servings in a cookie. And I don't know if
you've ever tried to cut a cookie into tenths and just eat 1/10 of a cookie. It's
probably pretty difficult and there's no regulation that forces organizations in the
cannabis industry to ensure that 10 milligrams are in each 10th of a cookie, so you
could have 1/10 of a cookie and you get 40 milligrams, or a 10th a cookie and 0
milligrams of THC. So, I think that first and foremost there, there probably should
be some additional oversight and some rules that dispensaries need to adhere to.
And it’s potential to be addictive and potential to overdose and doctor Tom
Crowley, who is Professor Emeritus at the University of Colorado in the
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Department of Psychiatry. did a study a few years ago about psychosis and a
correlation between marijuana use and psychosis.
In LAC#2’s forensic population, they observed:
I don't run into synthetics much anymore. The only people that I see, particularly
with the advent of legalized cannabis. I don't see much in the way of synthetics.
The only ones that I see generally are people that are on probation because it
doesn't show up on a drug test. So yeah, and people on parole, people that are on
parole if they have a medical card for well, let's him go ahead and use cannabis,
right? So, the only ones that I see are ones that are on probation and most of those
anymore understand that the synthetics are pretty dangerous. They can actually
induce a full-blown psychotic episode, landing in the hospital. Most people
anymore are aware of that and don't use Spice or any of the other synthetic. They
don't want to be hospitalized and a lot of them have seen that happen with some
of their peers and they don't want any part of that.
LAC#1 reflected the concerns in this theme this way:
It’s scary to believe that marijuana was never on the street black market, it was
always on the street. Getting factual information about the roulette of using a
substance and you don’t know what the outcomes can be powerful in prevention,
treatment, and intervention. Does this keep people from making the decision to
use? No. So without the science to demonstrate that it’s scary and dangerous, is a
historical fearmongering that we use with substances over time. And any
substance that was used in teas and elixirs, if you look at opiates and opium, of
course, they become more potent, more dangerous, of course, the effects are

86

factored the effects are greater when you eliminate the plant. This is true of any
known substance that is plant-based. When we look at refining heroin out of the
plant, or cocaine out of the coca plant, this isn’t a new process, it’s not often
applied to marijuana. This is something well known in our field and how people
use substances. The risk goes up when bang for the buck goes up, and you have to
have a bigger effect because the risk is too high in using the substance. This is big
business now, but this is not a new game. I have great concerns about synthetic
cannabinoids because we know very little about them. Again, when anything is
regulated or illegal it not only stops use on the street, but it also stops the science.
So, all the substances that are coming to market to get around the regulation
systems, like the spices and synthetic TCH are very scary because they are
chemical molecular compounds that we do not understand, we do not understand
how they alter the system, and therefore you can’t teach people effectively about
the potential risks. We don’t even know what they’re made of, and we don’t know
what people are using. The market is so adulterated now, with substances that are
legal to buy, legal to sell, and legal to use and will not show up in UA’s. This is
the best marketing scheme for anyone who is looking to get around a regulatory
system.
Theme 6: LAC Strategies for Prevention
The LAC participants in this study related their concerns about deficits in any
meaningful prevention strategies in treating CUDs, including a lack of funding, and
confusion that potentially exists from a lack of research and perspicuity, combined with a
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misunderstanding and misapplication of the current models in treatment This in their
view, hindered the development of evidence-based prevention strategies.
First, LAC#1’s observations are potentially instructive about constructing
meaningful psychoeducational prevention strategies observing:
I think the greatest thing that needs to be addressed in treatment and prevention
with substance use disorders is we don't teach how we do our work in models, so
in mental health, you learn CBT and yes, we apply these models in a cross
dynamic. So, we teach clinicians about the models they use eclectically so we say,
look, there's a biological construction, it's a disease, it's a disease. it's a disease.
We have people crossing models and understanding without the base knowledge
exactly of what tools they're using and how they're affected to use, and it confuses
the population receiving treatment. It makes us not be able to effectively talk to
them about why and how they're using, which means that treatment is not going to
be effective because you are not actually treating the issue, or you're creating
complicated models that are in conflict with each other. As my greatest issue in
education, the historical constructions around the socio-cultural intergenerational
perspectives of the dangerousness of substances. Again, often not based on
science, but rather based on a perception of the user, both by race, by poverty,
socioeconomic status, and the intergenerational impact in our system.
LAC#3 offered these reflections concerning this theme:
…you know the Reagan program, right? And so, and I just don't know. I have two
kids in elementary school right now and they're not receiving any education
around drugs and alcohol and. And I, I think that that is a failure in part in our
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society and they go to public school. I think that those programs were blamed for
not working, and so we've kind of swung the pendulum to almost really not talk
about it unless there's a problem and, and I think that's a misstep in the academic
system, I think that it is important to provide some type of program or education.
Starting in elementary school because we're seeing, you know I mentioned we
have an adolescent unit. We're seeing kids young. As you know, 8-9 years old.
that are trying substances here in the state of Colorado and then by the age of 24,
a lot of those individuals have become injection drug users. So, I think that we
can do a better job of providing education at an earlier age.
LAC#3 presented a concurring view about prevention:
I just think that there should be some warnings since it is legal in the state of
Colorado, you know a pack of cigarettes has warnings on the side as well, and
they've done a better job of packaging, but I'd still like to see it not be advertised
for children, so in the New York Times, I think it was last week there was an
article comparing like some kind of like Swedish fish product to a cannabis
Swedish fish product, and if you didn't recognize that very, very, very small
marijuana green leaf that's on the package, you might mistakenly give a child you
know a cannabis product because you're thinking you're giving a child as sweetest
Swedish fish, and it comes in a regular, you know bag that looks. Very similar to
Swedish fish, which I happen to love. Regular Swedish fish, you know, and so, I
think it's very dangerous and it reminds me of was the 50s when The Flintstones
were advertising Winston cigarettes. And I think that's kind of akin to what's
going on right now with the cannabis industry and unintentional marketing. That
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is, that is targeting. our children. So yes, I do want to see safer practices and more
education in place, and more disclosures. In order to keep people who are using
these types of products safer and better informed so that they are more
knowledgeable about the doses that they're ingesting.
Summary
Chapter 4 displayed a summary of synthesized data collection clusters and the
analysis procedures together with the results of six identified themes (Braun & Clarke,
2006; Creswell, 2006; Merriam, 2002, 2009). After identifying the theoretical
underpinnings under which I conducted the study and discussed related literature with the
development of common themes. This process sufficiently answered both research
questions through data collection and analytics derived from the participant interviews.
The clinician’s lived experiences of LACs treating CUDs Colorado following the
legalization of cannabis in Colorado generated six themes: a) LAC clinical experiences
that inform treating CUDs, b) LAC Clinical decision making, c) LAC treatment models,
theories, and interventions for CUD, d) LAC CUDs treatment implications since the
legalization of marijuana, e) LAC concerns about TCH dosage, purity, and safety, and f)
LAC strategies for prevention. Upon the conclusion of synthesizing the themes, I
developed and presented exemplifications of LAC responses related to the derived
themes by quotations from the data clusters generated in the MAXQDA20 qualitative
research software database audio-to-text interview transcripts.
The LAC participants shared their lived experiences and attitudes in treating
cannabis use disorders since the legalization of cannabis in Colorado via semi-structured
interviews and concluded with descriptive narratives of each clinicians’ experiences

90

about the research questions. Their answers resulted directly from data collection,
synthesis, and analysis from the derived participants’ perspectives. The interviews and
data collected from the participants resulted in the ability to display the participants’
professional, personal, and clinical experiences of their reciprocally stemming from
decision-making processes in the treatment of CUDs in Colorado since the legalization of
cannabis. I discussed the theory of relating one’s interpersonal, behavioral, and
environmental influences and summarized the contributing factors of their actions and
processes for decision-making with CUDs cases through the application of multi-modal
interventions drawn from reciprocal learning, integration, and practices of addictions
counseling therapeutics. In the final chapter, I will discuss the research findings,
recommendations for future research, and the potential implications of the study.

91

CHAPTER FIVE: CONCLUSION
Overview
The purpose of this qualitative phenomenological study was to acquire and
describe clinicians’ experiences and attitudes in treating cannabis use disorders in
Colorado since the legalization of marijuana. The purpose of this chapter was to discuss
the implications of the study’s findings and provide recommendations based on the
outcomes. The chapter begins with a summary and review of the outcomes of the study. I
present a synthesized discussion of the implications of the study corresponding to the
literature I reviewed. After describing the limitations of the study, I conclude the chapter
concludes with recommendations for future research in the field of behavioral health care
based on the findings. The research questions guiding this study were:
RQ1. What are the attitudes of licensed addiction counselors (LACs) in Colorado
concerning the treatment of Cannabis Use Disorders (CUDs)?
RQ2. What regulatory, personal, environmental, social, scientific, legal, or
clinical experiences influence the decision-making of LACs who treat
cannabis use disorders in Colorado?
Summary of Findings
Analysis of the data revealed six themes related to the LAC participants’ attitudes
in treating cannabis use disorders in Colorado, which describes their clinically identified
experiences that influence their treatment decisions. I used a qualitative
phenomenological method (Creswell, 2007; Merriam, 2009) to capture and explore
clinician’s attitudes and experiences influencing their decision-making. The concept of
reciprocal determinism or the interplay of personal, behavioral, or environmental
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influences, (Bandura, 1986, 1989, 2001, 2006) provided guidance to analyze and interpret
the contributing factors to the addictions counseling therapeutics base of knowledge in
the direction of identifying any regulatory, personal, environmental, social, scientific,
legal, or clinical experiences influencing their decision-making when treating cannabis
use disorders in Colorado.
Reciprocal determinism was a suitable theoretical base so the participants could
project clinical cognitive decision-making based on personal, behavioral, and
environmental factors because these are a strong impetus and motivator for treating
clients with CUDs. The theoretical social learning factors gleaned from the participants’
data, analogous to words, statements, and shared stories from the recorded study
interviews (reciprocally determined). This provided insight and definition into addiction
treatment praxis and the lived experiences of LACs in Colorado, and applicable with
patients treated in substance use in-patient and out-patient settings for cannabis use
disorder.
This applied theoretical perspective, conducted through the auspices of guided
interview questions, allowed the participants to share their attitudes as LACs in Colorado
treating CUDs and allow them to do so by sharing any personal, environmental, and
behavioral influences guiding their clinical decisions in treating CUDs.
Discussion
I drew the theoretical framework for this study from and relied on Bandura’s
conceptualization of reciprocal determinism derived from the social cognitive
theory that essentially posits the causation of social phenomenon is rooted in one’s
personal, environmental, and behavioral influences (Bandura, 1986). While the
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theoretical literature does not contain the application of this theory specifically to
clinicians’ experiences as LACs in Colorado treating CUDs, I adapted the social
cognitive theory for the participants to project clinical cognitive decision-making
based on personal, behavioral, and environmental factors because they were a strong
impetus and motivator for treating clients with CUDs. Therefore, I gleaned these
social learning factors from the participants’ data, analogous to words, statements,
and shared stories from the recorded interviews (reciprocally determined). The basic
idea of reciprocal determinism focuses on stimulus events transforming an
individual’s behaviors (Williams et al., 2010).
Discussion of Findings in Relation to the Theoretical Framework
I interpreted the discussion of the results of this research investigation from
the findings derived from participant interviews and verbatim transcripts from
voice-to-text processed with MAXQDA20 qualitative research software (Kuckartz
& Radiker, 2019). The findings of this study uncovered new information that
identified six themes from the processed participants’ interviews (Braun & Clark,
2006; Corbin & Strauss, 2007; Merriam, 2002, 2009). I used the constant
comparison methodology described by Corbin and Strauss (2007) for categorizing
and data clustering the participant’s transcribed interview text before data analysis.
In drawing the theoretical framework for this study from Bandura’s
conceptualization of reciprocal determinism, which he derived from social cognitive
theory, essentially posits the causation of social phenomenon was rooted in one’s
personal, environmental, and behavioral influences (Bandura, 1986)
Personal Factors
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Bandura (1989) found reciprocal interactions between thoughts, affect, and
behaviors. Personal factors reflect a person’s affective, interpersonal, and cognitive
perceptions. I produced the personal factors of how participants related their
personal and professional histories treating CUDs.
Behavioral Factors
Under the presuppositions within reciprocal determinism, people’s bidirectional environmental factors exert influence in a way people become both
producers and by-products of their environments. People’s interactions shape their
behavioral intentions from their thinking, values, beliefs, expectations, and selfperceptions (Bandura, 1986, 1989, 2001). Behavioral influences assessed from the
participants’ statements concerning their perceptions of treatment strategies
“directionally” deduced the dynamic environmental factors they experienced
working with cannabis use disorder clients.
Environmental Factors
Environmental influences are highly correlated with the interactions between
personal characteristics, environmental influences (Bandura, 2006), and social
influences, conveying information affecting human beliefs, expectations, emotional
reactivity, and relative cognitive competency. As participants reflected on their
experiences and field observations with clients with CUD, they revealed the
influences of multiple environmental factors in clinical decision-making and
treatment choices.
Theme 1: LAC Clinical Experiences that Inform Treating CUDs
All the participants described clinical experiences they believed relevant to
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treating CUDs through oral vignettes that were very rich, brief evocative
descriptions, or accounts of lived clinical experiences. The responses under this
theme revealed the participants' adeptness in multi-modal treatment practices
(Primm et al., 1999). One of the areas of concern was LACs now see actual physical
withdrawal and not merely psychological withdrawal with cannabis use. While this
does not appear to be severe or have the attending consequences of other abused
substances, clinicians expect to see increased irritability, sleep disturbances, and
appetite lessened. All of these seem to dissipate with about two weeks. This may be
attributable to marked increases in TCH potency and concentration observed from
numerous clinical experiences. One participant estimated previous cannabis
products contain between 3% to 5% THC, whereas now it may be upwards of 30%
which does not include cannabis concentrates.
Another concern arising from LAC clinical experiences is a small but
growing number of clients in which marijuana was potentially a major factor in
lethality, although most likely indirectly. One participant recalled two clients that
perceived their CUD was “killing them.” This appears to be a very curious and new
finding, in that when these clients attempt to stop (typically multiple times) they
struggle with eating and meeting other basic needs. Additionally, they may report an
increase in anxiety or depressive symptoms to the point of suicidality and/or a firsttime onset of psychosis. This results in erratic and unsafe behaviors, which
contributes to the risk of death or serious bodily injury.
The participants were unanimous concerning how clients with CUD tended
to overlook all evidence of THC as addictive. Clients appear not to have sufficient
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information about TCH, they do not know the risks, particularly the long-term risks.
One LAC participant stated, “…marijuana is addictive and there are a lot of people
that use marijuana that don’t think it is. And yet when you read the diagnostic
criteria in the DSM for CUD it is clearly addictive. It has the potential for addiction
and overdose…” It likewise seems to be a very settled matter of science and
practice with all the participants, THC is addictive, and there is a syndrome of
marijuana withdrawal.
The participants also collectively observed CUD suffers did not see CUD as
a disorder. From the clinical experiences of the participants, other treatment
providers can expect to see CUD most often in the context of polysubstance abuse.
It may be rare to find a client who is solely using cannabis and only meets the DSM
criteria for cannabis use disorder. One participant described their typical clinical
experience this way, “…so people come to see me, and they’ll say yes, I want to
work on my substance use disorder, I’m going to give up alcohol, but I’m still going
to use pot.” Conversely, in the context of treating prisoners and probationers in
forensic populations, one of the participants, an experienced certified treatment
provider for the Colorado Department of Correction, expressed how those
previously incarcerated for substance-related issues, upon release from prison
clients, miss marijuana. They shared, “…they may not miss the meth or the cocaine
or whatever, but they really miss the marijuana, and I don’t know why, but that’s
the one that they want to come back to.”
Another participant related a very interesting but unexpected clinical
observation from a large university methadone OTP (Opioid Treatment Program)
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with over 4,000 patients:
…so, in the state of Colorado, we are not required to test for cannabis, so in
many of the OTPs, this is not actually done. And the state of Colorado did
not consider cannabis positive in a urinalysis result to be something of an
infraction, so it doesn't necessarily restrict take-home medication for
methods. However, our organization has made the determination that people
with more disorder are at higher risk for diversion or unsafe behaviors with
regard to methadone take homes and so have determined to limit the number
of take-home bottles that a patient can receive if they meet criteria for
moderate or severe according to the DSM 5.
Paradoxically this LAC participant also revealed another experiential phenomenon
regarding cannabis administered in the OTP setting:
…there are shorter lengths of stay for people using marijuana when receiving
methadone treatment…it’s helpful to be on medication at least for opioid use
disorder or alcohol use disorder, and then we find that in a lot of cases that
cravings and the number of days used are decreased.
Theme 2: LAC Clinical Decision-Making
The study participants unanimously endorsed the basis of their clinical
decision-making in the treatment of CUS upon identifying the DSM symptoms for a
differential diagnosis, completion of standardized assessments, and using wellresearched and established standards (particularly those found at SAMSHA),
together with adequate supervision, as vital when making treatment planning
decisions. The participants all insisted the practitioner must determine whether their
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CUD is an issue requiring redress. This is a critical and foundational finding for this
study because the participants found greater than 95% of cannabis users do not have
symptoms rising to the level of the DSM criteria for CUD:
Use of cannabis for at least one year, with the presence of at least two of
the following symptoms, accompanied by significant impairment of
functioning and distress:
1.Difficulty containing the use of cannabis. They use the drug in larger
amounts and over a longer period than intended.
2. Repeated failed efforts to discontinue or reduce the amount of cannabis used.
3. An inordinate amount of time occupied with acquiring, using, or recovering
from the effects of cannabis.
4. Cravings or desires to use cannabis. This can include intrusive thoughts,
images, and dreams about cannabis, or olfactory perceptions of the smell of
cannabis, due to preoccupation with the drug.
5. Continued use of cannabis despite adverse consequences from its use, such as
criminal charges, ultimatums of abandonment from spouse/partner/friends, and
poor productivity.
6. Other important activities in life, such as work, school, hygiene, and
responsibility to family and friends are superseded by the desire to use cannabis.
7. Cannabis is used in potentially dangerous activities, such as operating a motor
vehicle.
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8. Use of cannabis continues despite awareness of physical or psychological
problems attributed to use, for example, anergia, motivation, and/or chronic
cough.
9. Tolerance to Cannabis, as defined by progressively larger amounts of cannabis
necessary to obtain the psychoactive effect experienced when using first
commenced, or noticeably reduced effect of the use of the same amount of
cannabis
10. Withdrawal, defined as the typical withdrawal syndrome associate with
cannabis, or a similar substance used to prevent withdrawal symptoms.
The status of the disorder can be further qualified as early or sustained remission.
An additional specifier for the status of the disorder is:
In a Controlled Environment, e.g., a treatment facility or correctional
facility with limited access to cannabis. The severity of the disorder also depends
on the number of symptoms noted:
•

Mild – Two or Three Symptoms

•

Moderate- Four or five symptoms

•

Severe- Six or more symptoms (American Psychiatric Association, 2013).
I detected two other highly significant areas of special focus with respect to LAC

clinical decision-making within this thematic category. First, the study participants were
again in complete accord concerning the necessity for clinicians to assess for
neuropsychological and neurophysiological processes in all substance abuse populations
and provide clients with psychoeducation to help them understand the effects of THC in
the brain. One participant stated how “…helping them understand how far along we are
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with understanding a general kind of framework as far as how compulsive substance
abuse creates disordered brain functioning.” Secondly, the study participants all shared
clinical observations regarding informing their decision-making by identifying the typical
finding of a history of trauma in substance abuse populations, including CUDs. One
experienced participant reflected on this:
…I look at the use of a substance as a deeper driving issue…to be deeper in terms
of specific problems or comorbidity like trauma. This is probably the biggest,
yeah trauma plays one of the biggest roles in comorbidity; could be physical,
emotional, or attachment trauma.”
This was also particularly significant for forensic populations with one of the specialists
remarking, “…I work a lot with trauma survivors for 16 years and I find a lot of
substance use disorders are rooted in a history of trauma.”
Theme 3: LAC Treatment Models, Theories, And Interventions for CUDs
The five participants followed a cognitive-behavioral approach primarily
informed by a harm-reduction model, contingency management, disease model, or clientcentered focus with repeated words from the participants to “meet the client where
they’re at.” All the participants argued against the moral model involving abstinence-first
and agreed concerning the need for the decriminalization of cannabis. The participants in
this study all utilized motivational interviewing techniques to facilitate change talk, and
resolve ambivalence, finding this a prime model and intervention for CUDs that helps
move clients through the stages of change. Another participant summarized the preferred
model of intervention suggesting:
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clinicians should understand that clients need to be ready for treatment, with the
best results in treatment outcomes occurring if the client is doing it for themself.
External influences have an effect on treatment outcomes, but lasting change is
associated with being motivated to benefit oneself. In other words, it has to move
from a punitive focus to an internal locus of control.
Theme 4: LAC CUDS Treatment Implications Since Legalization of Marijuana
One very significant treatment implication revealed since the legalization of
marijuana, was all the participants concurred on the need for removal of cannabis as
a Schedule I controlled substance and decriminalized. The Schedule I category
carries with it a pre-determined finding of no evidence of medicinal value. The
participants all shared how the only registered research-grade marijuana registrant
received authorization to grow marijuana for research at a secure facility under
contract with the University of Mississippi. This singular facility has access to
varying potencies and compositions along with marijuana-derived compounds also
available for study (Singh et al., 2008). They shared how a long and onerous
process could last for years. Considering greater barriers to cannabis research
includes adhering to purchasing all cannabis used for research purposes through the
National Institute on Drug Abuse (NIDA). The highest TCH level available to
researchers is 12.4%, however, strains in Colorado now average 18.7% TCH, with
some strains containing as high as 35% (Stith & Vigil, 2016).
One participant shared:
I would like to see the Feds get off of their conservative high horse and get
cannabis off the Schedule I classifications so that we can get vital research done.
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You’re not going to get any federal money for research as long as it’s a Schedule
I. So, if we can move the needle down a notch and some funding and research
done, that would be very, very helpful. There are dozens of cannabinoids that we
don’t know what they really do. Anecdotally, I have clients that say they get
significant benefits from CBD, and it will help with sleep, pain, and a lot of
different conditions. It would be nice to get some actual evidence of the use of
CBD to help these certain issues. It would also be helpful to do the same thing
with THC. We need to get the research done, we know more about most every
other substance and the mechanics of how they work than we do cannabis.
Another participant summarized this primary treatment implication since legalization
sharing:
I think when we can better science and really understand what’s unique about
those who struggle we have a greater opportunity to create effective treatment
options. But right now, they’re trying to treat with incomplete science means
we’re shooting darts in the dark. We’re facilitating the narrative that the substance
should not have an application when really every psychoactive substance is just a
chemical compound and it’s neither moral nor immoral.
Theme 5: LAC Concerns about TCH Dosage, Purity, and Safety
All the participants concurrently and urgently expressed apprehension about a lack
of research-based findings on the effects of THC. They generally do not have any
confidence in the medical efficacy of THC based upon research. They are likewise
unified in their concerns about their clinical experiences with the steadily rising
potency of cannabis and the potential adverse consequences of use worsening. This
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runs parallel to and concurrent with their even deeper concerns about synthetic
cannabinoids and concentrates as well. The participants perceived a grossly underorganized cannabis industry and market lacking sufficient oversight. One remarked,
So, I think that first and foremost there, there probably should be some
additional oversight and some rules that dispensaries need to adhere to and its
potential to be addictive and potential to overdose and doctor Tom Crowley,
who is Professor Emeritus at the University of Colorado in the Department of
Psychiatry. did a study a few years ago about psychosis and a correlation
between marijuana use and psychosis.
Another participant who is an expert clinician, trainer, and researcher reflected the
concerns under this theme this way:
Risk goes up when bang for the buck goes up, and you have to have a bigger
effect because the risk is too high in using the substance. This is big business
now, but this is not a new game. I have great concerns about synthetic
cannabinoids because we know very little about them. Again, when anything
is regulated or illegal it not only stops use on the street, but it also stops the
science. So, all the substances that are coming to market to get around the
regulation systems, like the spices and synthetic TCH are very scary because
they are chemical molecular compounds that we do not understand, we do
not understand how they alter the system, and therefore you can’t teach
people effectively about the potential risks. We don’t even know what
they’re made of, and we don’t know what people are using. The market is so
adulterated now, with substances that are legal to buy, legal to sell, and legal
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to use and will not show up in UA’s. This is the best marketing scheme for
anyone who is looking to get around a regulatory system.
Theme 6: LAC Strategies for Prevention
Finally, the participants in this study found a conspicuous absence of any
meaningful prevention strategies in treating CUDs, including a lack of funding, and
confusion that exists from a lack of cohesive research and perspicuity, together with
a misunderstanding and misapplication of current models and methods of treatment.
This significantly hinders the development of effective evidence-based prevention
strategies. An expert participant stated:
I think the greatest thing that needs to be addressed in treatment and prevention
with substance use disorders is we don't teach how we do our work in models, so
in mental health, you learn CBT and yes we apply these models in a cross
dynamic. So, we teach clinicians about the models they use eclectically so we say,
look, there's a biological construction, it's a disease, it's a disease. it's a disease.
But you’re self-medicating and that’s related to Khantzian’s self-medication
hypothesis. We have people crossing models and understanding without the base
knowledge exactly of what tools they're using and how they're affected to use, and
it confuses the population receiving treatment. It makes us not be able to
effectively talk to them about why and how they're using, which means that
treatment is not going to be effective because you are not actually treating the
issue, or you're creating complicated models that are in conflict with each other.
As my greatest issue in education, the historical constructions around the sociocultural intergenerational perspectives of the dangerousness of substances. Again,

105

often not based in science, but rather based in a perception of the user, both by
race, by poverty, socioeconomic status, and the intergenerational impact in our
system.”
Other findings within this thematic category included the need for testing of
retail cannabis products for dosage and purity, as well as packaging labels that
provide details about the contents and clearly visible warnings denoting THC
content and safety warnings. One participant recently encountered this in a widely
reported incident:
so in the New York Times, I think it was last week there was an article
comparing like some kind of like Swedish fish product to a cannabis
Swedish fish product, and if you didn't recognize that very, very, very small
marijuana green leaf that's on the package, you might mistakenly give a
child you know a cannabis product because you're thinking you're giving a
child as sweetest Swedish fish, and it comes in a regular, you know bag that
looks. Very similar to Swedish fish, which I happen to love. Regular
Swedish fish, you know, and so I, I think it's very dangerous and it reminds
me of was the 50s when The Flintstones were advertising Winston
cigarettes. And I think that's kind of akin to what's going on right now with
the cannabis industry and unintentional marketing. That is, that is targeting.
our children. So yes, I do want to see safer practices and more education in
place, and more disclosures. In order to keep people who are using these
types of products safer and better informed so that they are more
knowledgeable about the doses that they're ingesting.
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Another participant offered this thematic reflection:
I have two kids in elementary school right now and they're not receiving any
education around drugs and alcohol and. And I, I think that that is a failure
in part in our society and they go to public school. I think that those
programs were blamed for not working, and so we've kind of swung the
pendulum to almost really not talk about it unless there's a problem and, and
I think that's a misstep in the academic system, I think that it is important to
provide some type of program or education. Starting in elementary school
because we're seeing, you know I mentioned we have an adolescent unit.
We're seeing kids young. As you know, 8-9 years old. that are trying
substances here in the state of Colorado and then by the age of 24, a lot of
those individuals have become injection drug users. So, I think that we can
do a better job of providing education at an earlier age.
In sum, the participants sensed the need for increasingly efficacious
prevention and interventions programs targeting kids and adolescents because they
present as most at risk. They argue the essential need to appropriately monitor
longitudinal outcomes in Colorado. This is imperative for the participants because
education regarding “safer” use can help to detect cannabis-related impairment
reductions. The participants concur generally with the need for research that
identifies risk modifiers that distinguish between medicinal vs. recreational use.
Because of their urgent concerns associated with an unregulated cannabis market
whose products sell or are distributed in legalized dispensaries and black markets
(Sahlem et al., 2018).
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Implications
This study may offer highly significant insights and information drawn from
the lived experiences of expert field practitioners who treat CUDs. The outcomes I
ascertained revealed critical new information that provides new platforms for
continued research and practice. This study has practical implications for treatment
providers in dual diagnosis service delivery areas including in-patient and outpatient
substance use treatment facilities as well as opioid treatment programs. Since the
legalization of both medical and recreational marijuana in Colorado, I uncovered a
variety of complex issues revealed through the lived experiences and attitudes of
front-line expert LACs who practice in Colorado and treat CUDs. The ability to
accurately diagnose CUDs and their co-occurring disorders correlate with better
treatment outcomes.
Within the theme for clinical experiences that inform the treatment of CUDs,
highlighted the participants' skills in multi-modal treatment practices. The
participants' concern focused on the period following the legalization in Colorado
when clients experience physical as well as psychological withdrawal from cannabis
use. Clinical experience with this phenomenon appears comparatively less severe
than with other abused substances. Clinicians can expect to see typical withdrawal
symptoms including irritability, sleep disturbances, and decreased appetite, with all
aliments resolving in about two weeks corresponding with the reviewed literature
findings (Budney & Hughes, 2006).
The results of this study imply clinicians may encounter a small but growing
number of clients in which marijuana withdrawal syndrome may indirectly be a
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major factor in lethality, which may be associated with multiple attempts to quit
using cannabis. They may struggle to meet basic needs and report poor appetites,
not eating, and an increase in anxiety or depressive symptoms to the point of
suicidality and/or the first onset of psychoses. This may result in erratic and unsafe
behaviors, which increases the risk of death or serious bodily injury. The
participant’s clinical experience includes an overall tendency of clients with CUD to
overlook evidence of THC as addictive and a disorder. The participants attributed
this to insufficient information about the effects of THC, and the lack of awareness
of the risks, particularly the long-term risks of cannabis use. This correlates with the
reviewed literature, which details how cannabis can lead to problem use (CUD) and
become a form of addiction in severe cases. Recent data suggested 30% of cannabis
users also reported some degree of CUD. People who start using marijuana before
the age of 18 are four to seven times more likely to develop CUD than mature
adults. (Winters & Lee, 2008). Nine percent of people who use marijuana will
develop a dependency and approximately 17% of those who start using it in their
teens (Center for Behavioral Health Statistics and Quality, 2013). In 2015, 4 million
people in the U.S. met the diagnostic criteria for CUD (Substance Abuse Center for
Behavioral Health Statistics, 2018), and 138,000 voluntarily sought treatment for
their marijuana use (Office of National Drug Control Policy, 2020). On average,
adults seeking treatment for marijuana use disorders have used marijuana nearly
every day for more than 10 years and have attempted to quit more than six times
(Diamond et al., 2006).
The participants’ clinical experience with CUD suggested treatment
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providers can expect to see CUD most often in the context of polysubstance abuse,
and in forensic populations, upon release clients are apt to return to using marijuana
as a preferred substance. An unexpected research implication arose through the
auspices of a skilled and experienced participant in a large methadone OTP (Opioid
Treatment Program) with over 4,000 patients. Based on their clinical experience
they suggested patients with more CUD disorder presented at higher risk for
diversion or unsafe behaviors with regard to treatment take-home medications and
were limited in the number of take-home bottles if they met the criteria for moderate
to severe CUD.
Paradoxically, this same participant revealed another clinical phenomenon
associated with the administration of THC in the OTP setting with shorter stays and
reduced cravings for opiates. The results of this study, drawn from factors that
contribute to the participant’s clinical decision making, indicated the treatment of
CUDs required evaluation from the DSM symptoms to produce a differential
diagnosis, as well as complete histories and standardized assessments. The use of
well-researched and established protocols, especially from the Substance Abuse and
Mental Health Services Administration (SAMSHA) is essential to making an
accurate diagnosis and designing effective treatment planning. The participants fully
endorsed those practitioners who treat CUDs as having adequate supervision and
training in order to competently practice within the scope of the discipline. This is a
critical and foundational implication from the study results because the participants
found that greater than 95% of cannabis users do not have symptoms that rise to the
level of the DSM criteria for CUD.
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Drawn from the experiences informing the participant’s clinical decisionmaking was the finding that clinicians must assess for neuropsychological and
neurophysiological functioning and provide clients with psychoeducation to help
them understand the effects of THC in the brain and how compulsive substance
abuse creates disordered functioning. Another highly significant area of special
focus the participants identified as essential in making quality treatment decisions
was a typical finding from clinical observations of a history of trauma in substance
abuse populations, including CUDs. Therefore, clinicians can expect to encounter a
history of trauma, and carefully conduct an assessment.
The treatment models and theoretical orientations and CUD interventions of
the study participants used a cognitive-behavioral approach primarily
complemented by a harm reduction model, contingency management, drawn from
the disease model. All participants reported following a client-centered approach
and used a similar language of “meet the client where they’re at.” They also
collectively argued against the moral model involving abstinence first and endorsed
the decriminalization of cannabis.
All the participants utilized motivational interview (MI) techniques to
facilitate change talk, resolve ambivalence and found this a prime model, modality,
and intervention for CUDs because they show the greatest promise. Motivational
enhancement therapy is a systematic form of an intervention designed to facilitate
internally motivated change. The MI intervention and modality does not attempt to
“treat” the person but draws on the extant internal resources for change and
engagement in treatment. The participants acknowledged people with CUDs often
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also suffer from other co-morbid psychiatric disorders, particularly those with heavy
use and chronic mental disorders. The behavioral treatments they deploy were found
helpful in reducing marijuana use and entering recovery (Di Forti et al., 2019).
Another shared thematic urgent concern of the participants surfaced
concerning the lack of research-based findings of the effects of TCH. They also do
not have confidence in the medical efficacy of TCH because of the deficits of
science-based knowledge in this area. This concern runs parallel to a unified
concern of their experience with what appears to be a steadily rising potency of
cannabis and the potential worsening of adverse consequences.
The participants perceived a grossly under-organized cannabis industry and
market without sufficient oversight and quality controls. One participant framed this
stating:
Risk goes up when bang for the buck goes up, and you have to have a bigger
effect because the risk is too high in using the substance. This is big business
now, but this is not a new game. I have great concerns about synthetic
cannabinoids because we know very little about them. Again, when anything
is regulated or illegal it not only stops use on the street, but it also stops the
science. So, all the substances that are coming to market to get around the
regulation systems, like the spices and synthetic TCH are very scary because
they are chemical molecular compounds that we do not understand, we do
not understand how they alter the system, and therefore you can’t teach
people effectively about the potential risks. We don’t even know what
they’re made of, and we don’t know what people are using. The market is so
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adulterated now, with substances that are legal to buy, legal to sell, and legal
to use and will not show up in UA’s. This is the best marketing scheme for
anyone who is looking to get around a regulatory system.
The identified LAC strategies for prevention revealed and the participant’s
concerns and recognized a conspicuous absence of any meaningful prevention
strategies in treating CUDS, including a lack of funding, and an attending confusion
that exists from a lack of cohesive research and perspicuity that helps guide clients.
The participants alluded to misunderstandings and misapplications of current
models and methods of treatment significantly hindering the development of
effective evidence-based prevention strategies.
Participants would like to see an integration of retail testing for cannabis
products for dosage and purity, as well as packaging labels that provide details
about the contents, along with clear and visible warnings that differentiate the
presence of THC content to prevent children from mistakenly ingesting THC.
Finally, the participants perceived a wholesale lack of any drug abuse
prevention education, and kids as early as 8-9 years old are trying substances in
Colorado. Many of those individuals become injection drug users who are seen in
the OTP treatment centers. The participants sense the need for increased
intervention and prevention programs targeting kids and adolescents because they
are most at risk with longitudinal studies that monitor the outcomes in Colorado.
Education regarding “safe” can be of great benefit to detect cannabis-related
impairment reductions.
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Delimitations and Limitations
I made certain design decisions that defined the boundaries of the study. The
delimitations section below explains those choices. Additionally, I identified
potential weaknesses of the study that were beyond my control due to the focus of
the study. I describe the limitations in the following section.
Delimitations
The purpose of the qualitative phenomenological study was to access and
acquire clinicians’ experiences and attitudes in treating cannabis use disorders in
Colorado since its legalization. For that reason, I defined several boundaries to
focus the study. I chose a qualitative phenomenological design because the study
intended to allow participants to describe their clinical experiences. Bandura’s
(1989) social cognitive theory with its concepts of reciprocal determinism formed
the theoretical framework for the study and is appropriate to give voice to those
with similar experiences of a specific phenomenon (Creswell, 2013; Husserl &
Kerson, 1980;). In this case, the lived experiences and attitudes of LACs in
Colorado who treat CUDs. The choice of selecting LACs in Colorado was one of
convenience to my location. Other factors presented in the areas of experiences of
substance abuse treatment encounters.

I restricted participation in the study to

only those who are active LACs in Colorado to ensure this criterion met the focus of
the study.
Limitations
There are several potential limitations in this study based on its focus, design,
sample size, and study population. Because of its qualitative and phenomenological
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nature, the results are not generalizable and may be difficult to duplicate. The sample size
of five is small but acceptable for a qualitative phenomenological study due to data
saturation, although this may have produced a limited view of LACs in Colorado who
encounter and treat CUDs.
Another limitation inherent to the study was I am a licensed professional
counselor (LPC) in Colorado with considerable clinical experience treating substance use
disorders. I, therefore, took care to bracket out my experiences as a clinician, but there
remained the possibility of bias in the description of the findings. In addition to
bracketing, I took steps to minimize this limitation through member checking of the
collected and analyzed data, but I may not have eliminated my biases.
Recommendations for Future Research
A major concern surfaced by the study’s participants highlighted the steadily
increasing potency of marijuana over several decades in confiscated samples. The
average TCH content in the early 1990s in confiscated marijuana samples was less than
4% (Mehmedic et al., 2010). In 2018 it had grown to more than 15% (Freeman et al.,
2014). Researchers do not yet know the attending consequences when exposing the body
and brain (particularly the developing brain) to high concentrations of THC, nor whether
the increased emergency department visits detected in the literature review related to the
rising potency in those who test positive for THC. Research efforts in this area are
recommended to inform users of any correlation between the believed strength of the
marijuana they are using and understand the dynamics of potency variations.
An additional concern with medical marijuana highlighted the minimal
knowledge regarding the hundreds of unknown active chemicals in botanicals such as
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marijuana. THC has known adverse health effects such as THC-induced cognitive
impairment. Colorado has nevertheless legalized the dispensing of marijuana and its
extracts to people with a range of medical conditions. Further research can assist in
determining the efficacy in treating behavioral health disorders because the FDA has not
approved any medications for the treatment of CUDs.
Further research on the effects of THC cannot proceed until removal of the
impediment of prohibiting possession of marijuana due to its current scheduled
classification, and designation of having no known medical use federally. The effects of
legalizing cannabis on treatment and research priorities for CUDs require further
research. Current treatment approaches, over multiple trials, resulted in only modest
observed efficacy and interventional durability (Sahlem et al., 2018). Available CUD
treatment trials demonstrated abstinence durability as generally poor, with one exception
that combined CBT with abstinence-based contingency management (CM), which
achieved an abstinence rate of 37% that persisted for one year (Budney et al., 2006).
It seems likely legalization will increase the need for efficacious intervention and
prevention programs for CUDs, particularly those that target adolescents. Sahlem and
associates summarized this in their discussion of public health outcomes affected by the
increases and unlimited cannabis availability:
…There have been several investigations that have evaluated the efficacy of
school-based prevention programs. The majority of such investigations were
randomized controlled trials focused on universal prevention among middle
school students…reviewed trials of interactive programs which emphasized skillbuilding and peer interactions rather than relying on a traditional didactic, lecture-
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style model. These programs yielded a small, pooled effect on reducing cannabis
use, but did not reduce the intention to use or improve refusal skills relative to
control conditions... a systematic review of middle school-based programs
revealed few statistically significant positive effects of active interventions when
compared to control conditions (Sahlem et al., 2018).
The study participants urgently recommend the further development and
implementation of prevention and intervention programs for adolescents. The available
programs have only small beneficial treatment effect sizes, making this research area
vitally important given cannabis will be more
…acceptable as its perceived risk continues to fall…programs utilizing
comprehensive educational programs would likely have the largest overall impact
given the rate of conversion to CUD appears to be highest in this group (Sahlem
et al., 2018).
The potential implications of legalization and the prevention of CUD, along with the
increased vulnerability of adolescents to cannabis’ negative effects, would be reduced by
programs that, “delay the onset of use beyond this critical time and be of particular
benefit in reducing the adverse impacts of cannabis use” (Sahlem et al., 2018, p.220).
The study participants unanimously suggested researchers should focus on more
effective treatment availability. Regrettably, the majority of psychosocial treatments lack
durability, and no pharmacological treatment attained FDA approval for the reduction of
cannabis use. The study participants likewise perceived the best way to avoid the adverse
effects of cannabis use is through harm reduction approaches that may provide individual
patients the freedom and autonomy to set their own self-directed treatment goals,

117

particularly for those who, “recognize that their use of cannabis is associated with harm,
but do not want to abstain entirely. Harm reduction approaches may modify both how
and what clinicians communicate to patients in treatment settings…” (Sahlem et al.,
2018).

Summary
I provided previously unknown attitudes and experiences of LACs who treat

cannabis use disorders in Colorado since its legalization based on the results of this study.
This information will help professional addictions practitioners and substance use
treatment facilities who encounter those with CUDs. Utilizing a qualitative
phenomenological research method, I explored LACs’ treatment experiences with CUDs
in a variety of treatment settings. Semi-structured interview questions guided the inquiry
and increased ways of understanding the CUD phenomenon (Merriam, 2009). Research
questions provided structure and guidance for the inquiry, and I expounded on themes
derived from themes, which emerged as each contributor revealed their experiences that
inform their treatment of CUDS, as well as their decision-making processes. The study
participants provided key insights into their treatment models and modalities, theories,
and interventional protocols for treating CUDs. I explored a vitally important theme
related to treatment implications since the legalization of marijuana and uncovered new
information. The participants expressed concern about the unknown effects of THC and
evidence-based research as they remain skeptical about the medical efficacy of
marijuana. The dosage, purity, and safety of the products in the cannabis market,
including retail and black-market sources, were a special focus of the participant’s
concerns. The participating LACs recommend emphasizing developing effective
treatments and making them available as soon as possible.
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All the study participants related experiences by recalling events, scenarios, or
personal experiences that warrant changes in the way providers manage CUDS. Based on
the findings, I suggest the clinical experiences of LACs who treat CUDS should be
considered and applied to improvements in the development of interventional strategies
for marijuana users and consumers. Revealing their field experiences greatly contributed
to a better understanding of the behavioral sciences and human services disciplines.
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Please note that this exemption only applies to your current research
application, and any modifications to your protocol must be reported to the
Liberty University IRB for verification of continued exemption status. You may
report these changes by completing a modification submission through your
Cayuse IRB account.

If you have any questions about this exemption or need assistance in
determining whether possible modifications to your protocol would change
your exemption status, please email us at irb@liberty.edu.
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APPENDIX B: CONSENT FORM

Consent

Title of the Project: Clinicians’ Experiences and Attitudes Treating Cannabis Use
Disorders in Colorado: A Qualitative Inquiry Since the Legalization of Marijuana in
Colorado

Principal Investigator: Michael Leiker, Doctoral Candidate, Liberty University

Invitation to be Part of a Research Study

You are invited to participate in a research study. In order to participate, you must be 18
years of age, and a Licensed Addiction Counselor (LAC) in Colorado and have treated
Cannabis Use Disorders (CUDs). Taking part in this research project is voluntary.

Please take time to read this entire form and ask questions before deciding whether to
take part in this research project.

What is the study about and why is it being done?

The purpose of the study is to fill a gap in the attitudes and practices of Licensed
Addiction Counselors and the treatment of Cannabis Use Disorders in Colorado. The
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current state of generally accepted best practices among clinicians in Colorado would be
better understood if their therapeutic experiences, attitudes, and actions could be sampled
and recorded. Colorado’s licensed addictions professionals should be tapped as a rich
source of the effects of marijuana use, so that meaningful trends, themes, and patterns can
be identified so that overall treatment outcomes might be improved. This study seeks to
improve addictions counseling therapeutics derived from the lived experiences of LACs
who treat cannabis use disorders.

What will happen if you take part in this study?
If you agree to be in this study, I will ask you to do the following things:
1. You will be meeting with Michael Leiker via a confidential phone number, and a
series of questions will guide the interview. This interview would probably last
for approximately 30 minutes, and the interview and an audio recording will be
made.

2. During the phone interview, a series of study questions will guide the interview to
discover what informs your decisions about treatment of cannabis use disorders.

3. The interview questions are designed to allow you to describe your personal
attitudes concerning the treatment of Cannabis Use Disorders (CUDs).
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How could you or others benefit from this study?

Participants should not expect to receive a direct benefit from taking part in this study.

Benefits to society include, or potentially include implications for prevention and
community-based treatments that are informed by research and the clinical experience
and attitudes of LACs. The attitudes and lived experiences of LACs in Colorado can
vitally inform treatment practices and interventions through the stories of field
practitioners using their own experiences in treating CUDs, as described as their
narratives are explored and described in their own words.

What risks might you experience from being in this study?

The risks involved in this study are minimal, which means they are equal to the risks you
would encounter in everyday life.

How will personal information be protected?
The records of this study will be kept private. Research records will be stored securely,
and only the researcher will have access to the records.
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•

Participant responses will be anonymous. Participant responses will be kept
confidential through the use of identifying a participant by a numerical code only.
The interviews will be conducted in a location where others will not easily
overhear the conversation.

•

Data will be stored on a password-locked computer database, and the database
will be encrypted by a passcode and may be used in future presentations. After
three years, all electronic records will be deleted.

•

Interviews will be recorded and transcribed. Recordings will be stored on a
password-locked computer for three years and then erased. Only the researcher
will have access to these recordings.

How will you be compensated for being part of the study?
Participants will not be compensated for participating in this study.

Is study participation voluntary?
Participation in this study is voluntary. Your decision whether to participate will not
affect your current or future relations with Liberty University. If you decide to
participate, you are free to not answer any question or withdraw at any time without
affecting those relationships.
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What should you do if you decide to withdraw from the study?

How to Withdraw from the Study
If you choose to withdraw from the study, please contact the researcher at the email
address/phone number included in the next paragraph. Should you choose to withdraw,
data collected from you will be destroyed immediately and will not be included in this
study.

Whom do you contact if you have questions or concerns about the study?
The researcher conducting this study is Michael Leiker. You may ask any questions you
have now. If you have questions later, you are encouraged to contact him at xxx-xxxxxxx, xxxxxxxxxx@gmail.com. You may also contact the researcher’s faculty sponsor,
Dr. Richard Green, at xxxxxxx@liberty.edu.

Whom do you contact if you have questions about your rights as a research
participant?
If you have any questions or concerns regarding this study and would like to talk to
someone other than the researcher, you are encouraged to contact the Institutional
Review Board, 1971 University Blvd., Green Hall Ste. 2845, Lynchburg, VA 24515, or
email at irb@liberty.edu
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Your Consent

By signing this document, you are agreeing to be in this study. Make sure you understand
what the study is about before you sign. You will be given a copy of this document for
your records. The researcher will keep a copy with the study records. If you have any
questions about the study after you sign this document, you can contact the study team
using the information provided above.

I have read and understood the above information. I have asked questions and have
received answers. I consent to participate in the study.

The researcher has my permission to audio-record me as part of my participation in
this study.

____________________________________
Printed Subject Name

____________________________________
Signature & Date
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APPENDIX C: PARTICIPANT RECRUITMENT LETTER

To: Colorado Licensed Addiction Counselors (LACs):
As a graduate student in the School of Behavioral Science at Liberty University, I am
conducting research as part of the requirements for a doctoral degree. The purpose of my
research is to interview Licensed Addiction Counselors (LACs) in Colorado and record
how they describe their personal attitudes concerning the treatment of Cannabis Use
Disorders (CUDs), and also how LACs would describe what influences their decision
making in the treatment of CUDs. I am writing to invite eligible participants to join my
study. Participants must be 18 years of age or older, are a Licensed Addictions Counselor
in Colorado, and have Cannabis Use Disorder treatment experience. Participants, if
willing, will be asked to be interviewed and audio-recorded, and transcribed. The phone
interview will be guided by participant interview questions. The purpose of the recorded
interview is to access your personal, professional, and clinical experiences treating clients
who present with marijuana-related mental health problems. It should take approximately
thirty minutes to complete the procedure listed. Participation will be completely
anonymous. Names and other personal identifying information will be collected for
screening purposes, but the information will remain strictly confidential.
In order to participate, please contact me at xxx-xx-xxxx to schedule a confidential study
interview, or email address xxxxxxxxxx@ gmail.com.
Participants will not be compensated for their participation in the study.
Sincerely,

144

Michael Leiker
Doctoral Candidate, Liberty University School of Behavioral Sciences
xxx-xx-xxxx
xxxxxxxxxx@gmail.com
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APPENDIX D: SAMPLE OF PARTICIPANT TRANSCRIPT

Audio file
Transcript

Leiker
Well, thank you. So, I've got a a set of interview guide questions, so I'm just going to start
at the top.
Leiker
Yeah, what? What experiences do you have, say treating or dealing with marijuana
related behavioral health problems?
LAC#5
Yeah, uhm.
LAC#5
Quite a bit, actually. Let let's see I've I guess I've been in a behavioral health and
addictions field for about 8 years now, and uh, started as a.
LAC#5
Like a.
LAC#5
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A clinic assistant Slash drug monitoring technician for a uh.
LAC#5
Place called Arapahoe house. Actually, probably heard with them. And, uh.
LAC#5
Yeah, and uh, kind of worked my way up with that, uh, into some more, some even more
clinical roles as a therapist starting in the like DUI services so clients that were only in
treatment because they were court ordered from a DUI case.
LAC#5
Or they were anticipating being court ordered because of a DUI up to.
LAC#5
Uh, intensive outpatient programs, UM.
LAC#5
Jail settings, school settings. Psych hospital settings. Kind of a bit of a lot of.
Speaker 1
Different levels of care and settings, and, uh, marijuana.
LAC#5
I think, especially in Colorado, probably is a is fairly prevalent, and, uh, you know, you
see, you definitely see.
LAC#5
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Challenges and, uh, uh, symptoms that come up for patients, uh.
LAC#5
You know, oftentimes those are underlying. UM, sometimes you know they have been.
LAC#5
Likely caused by marijuana use, but usually they come like in combination with them.
Leiker
Good, let's talk about these then as we move through these, we're about to capture. Now
some of those unique themes from us. So what? What guides your clinical decision
making?
In treating you know kids and adults with cannabis you know marijuana related
problems.
LAC#5
Yeah, so it would be the first things that come to mind is a just like a.
LAC#5
Diagnostic criteria of cannabis use disorder. So looking at the DSM there, uhm in
addition to.
It's order.
LAC#5
I have quite a bit of background working within the DSM criteria and determining.
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LAC#5
A level of care options UM.
LAC#5
What's a pretty big part of my practice is, uh?
LAC#5
Just looking at the.
LAC#5
Neuroscience, and uh yeah. When appropriate, providing psychoeducation for the client
around that.
LAC#5
Uhm, so just helping them understand, uh?
LAC#5
You know what happens, uh, in the brain.
LAC#5
As it relates to UM?
LAC#5
Addiction UM and.
LAC#5
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Yeah, just.
LAC#5
Helping them understand how far along we are with understanding that certainly more so
than ever before, although there's still probably a lot of unknowns, but just get giving
them a a general kind of framework to work with as far as how those that type of you
know compulsive substance abuse.
LAC#5
Becomes disordered.
So, like, uh, particularly personally, but also professionally. One of my biggest concerns.
LAC#5
Around marijuana use is kind of the, uh.
LAC#5
What sometimes seems like a.
LAC#5
Widespread belief, uh, that marijuana is a.
LAC#5
That there's nothing risky about marijuana use. Uhm, I have thought and said at times in
the past that maybe one of the biggest.
LAC#5
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Risks related to marijuana use is just that attitude that there are no risks, and we've
obviously known that to not be the case.
LAC#5
This, uh, I think there's in my experience and I don't have like the most up-to-date
information about laws and so forth, but in my experience, last I checked, even with
medical marijuana, you know, being in Colorado for many years.
LAC#5
At this point is that they still don't quite know what to do with, uh.
LAC#5

LAC#5
With that as it relates to a DUI or DWI's you.
LAC#5
You know it's a bit trickier to test somebody for that on the spot as a.
LAC#5
As opposed to alcohol, uhm?
LAC#5
You know there's this, really.
LAC#5
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You know common perception or attitude, I think.
LAC#5
Of like oh marijuana is legal now marijuana is legal. It can't be bad and I think that that's
really a dangerous. I don't think marijuana is a bad thing. I think you know my lens as a.
LAC#5
Addiction counselor is that of which you know it's all about what is our relationship to
the substance and what can be.
LAC#5
Kind of a saving grace for one person that could be used medicinally or that can have a
lot of great benefits for one person it could.
LAC#5
You know, potentially kill somebody else. Uhm, on some level, uhm or or create a.
LAC#5
Just some kind of a really, uh?
LAC#5
Just health impacts, so uh.
LAC#5
Yeah, I think, uh, attitudes of the general public and the way, UM.
LAC#5
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Like, uh, the law is managing if you will, or navigating uh enforcement things of that
nature in addition to UM.
LAC#5
Just that.
LAC#5
Younger people come.
LAC#5
Using marijuana and not to mention the uh.
LAC#5
Uhm, just the potency levels. Nowadays it's just there's a lot to be. There's a lot that.
Leiker
Yeah, I'm going to talk about that here in just a minute. OK? Those are great points.

So as we move, we're moving that way as well.
Leiker
What are your? What are your thoughts and feelings?
Leiker
About legalization.
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Leiker
Of marijuana.
LAC#5
Yeah, I support.
Leiker
In Colorado.
LAC#5
I I definitely support UM legalization UM.
LAC#5
I don't know where.
LAC#5
All that tax money is going exactly. I'm sure they've had a lot of.
Leiker

Leiker

LAC#5
Great ideas for where that could go and where that should go. I think probably come.
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LAC#5
Uh, it needs to be a lot of that, uh, ideally in my opinion, should be funneled into very
specific.
LAC#5
Areas like treatment and prevention and.
LAC#5
So forth, but ultimately I support legalization as opposed to as opposed to.
LAC#5
You know, prohibition and I certainly support, uh?
So now could you describe?
Leiker
Your models or models or theories or strategies.
Leiker
When you're, you know, treating when you're thinking about treating.
Leiker
Disorders and for that matter polysubstance abuse. But maybe you have a particular
model.
Leiker
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Theory and strategy, that's.
Leiker
May be standardized or preferred. I wonder if you could share that.
LAC#5
Yeah, definitely well. The first thing that comes to mind for me is I.
LAC#5
I mean, there's this really wonderful documentary that you may have seen or.
LAC#5
I mean it's called a pleasure unwoven
LAC#5

And uh, it goes in. It's only about an hour long and I think its award-winning. It's it's
pretty great, but it poses the argument of his addiction.
LAC#5
Is it a choice or is it a disease and I definitely believe in the disease model. I definitely
believe that there's kind of four categories of use with starting with non-use.
LAC#5
Uh, use abuse and addiction and that a significant amount of people you know in our
world.
LAC#5
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Abuse substances and experience unmanageability to their lives because of it and less
amount of people but still a significant amount of people it develops to addiction. So, I
believe strongly in the disease model.
LAC#5
Uhm, as far as an approach goes, uhm?
LAC#5
Definitely a motivational interviewing is huge. Uhm, uhm?
LAC#5
And in tandem with, uh?
LAC#5
Kind of a, uh, CBT or DBT approach? Uh, mindfulness, space all of these things are,
UM, kind of what I
LAC#5
That's how I would summarize my approach with most patients.
LAC#5
Yeah, it's called it's called pleasure unwoven
Leiker
LAC#5
So what I'll tell you about?
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LAC#5
To answer that is really mostly falls under the umbrella of motivational interviewing.
LAC#5
Uhm, so really, just uh.
LAC#5

LAC#5
Kind of a person-centered like strength-based.
LAC#5
Uh, uh.
LAC#5
It's extremely.
LAC#5
Compassionate, nonjudgmental approach where I'm going to meet the person where
they're at and I'm not going to. I'm not going to set.
LAC#5
A ton of expectations for them or goals for them. I'm going to help them.
LAC#5
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You know, identify what they want to work on and what they want to work toward, but
not really having an agenda for that client. Uh, a lot of psychoeducation around things
like.
LAC#5
Uh, uhm.
LAC#5
And really, looking at where they're at through the lines of like the.
LAC#5
Stage of change models. So yeah so identifying.
Leiker
They did finish Fab 5.
LAC#5
Where they're at there?
Leiker
You find most people are in a sort of a.
Leiker
Maybe pre contemplative, obviously. Or do they?
Leiker
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It can't move from the, you know.
Leiker
The contemplative kinds of things. Or do they show up, you know, sort of actively
seeking. They're actively involved in the change.
Leiker
Right?
LAC#5
You know, it's really. It can be really tricky, and I think you can talk to 10 different
collections and get several different answers. As far as like where a particular patient is
and the stages of change.
LAC#5
Uhm, but honestly I think most clients who are in treatment or seeking treatment.
LAC#5
Tend to be in those earlier stages, pre contemplative or contemplative.
LAC#5
You know, a lot of ambivalence with these folks, which speaks to that contemplation
stage the.
LAC#5
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The way I was taught and how to work with the stages of change might be really unique,
uhm, but.
LAC#5
Honestly, I think people usually are not in those later stages of change. Usually in my
experience.
LAC#5
If someone in the later stages have changed, they're not looking for my help.
LAC#5
And there.
Leiker
Like they're functioning. There might be those people you said about who have a
relationship with cannabis that.
Leiker
Typically, with just cannabis problems, or is it more Brandon polysubstance abuse where
cannabis is involved?
LAC#5
Uh, I would say the latter more polysubstance with cannabis involved.
Leiker
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And in that context, then, which seems to be another theme that's been identified in this
study.
You know, for example, do they say? You know I'm having problems with opiates.
Leiker
But I use cannabis, which is OK, you know right?
Leiker
Is that is that so the presentation? Or is it something else in your practice?
LAC#5
Yeah, most frequently a cannabis.
LAC#5
I would not is not the primary concern of the patient and it is not the primary.
LAC#5
Diagnosis, as far as I'm concerned.
LAC#5
Uh, you know, kind of the lesser.
LAC#5
Of evils if you will.
LAC#5
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Uhm, there have been, uh.
LAC#5
Couple cases that I've been involved in and, and I mean like a very small amount like
probably less than five cases over 7-8 years in which.
LAC#5
Marijuana was actually like marijuana in and of itself was actually a.
LAC#5
Uh, a major factor in just the unmanageability and essentially just ruining a person life
and out of those there have been a couple occasions where that patient was very aware
and very vocal of that of marijuana is killing me. More specifically, eating habits and
appetite. I’ve had clients experience needing marijuana in order to eat and when they
attempted to cease use of the substance they struggled with eating, and other basic needs
sometimes too. Also, client’s marijuana use leading to them experiencing an increase in
anxiety or depressive symptoms to the point of suicidality or first-time occurrence of
psychosis. Erratic and unsafe behaviors often resulting.
LAC#5
Essentially so I have seen that as well, which is you know. Again, maybe rare, but
definitely possible.
Regarding the lack of regulating THC dosage purity, we were talking about that.
Leiker

163

For both medical and recreational users.
Leiker
Dosage curing
Leiker
Do you have any concerns about what?
Leiker
Thinking well themselves into in terms of.
LAC#5
Yeah, I just think, uh, people, uh, don't have all the information and uh, don't know the
risks, particularly the long-term risks associated with their behaviors and, uh.
LAC#5
You know there's it's easy to.
LAC#5
It's easy to, uh, to look the other way when that information does come in person way,
and they just experience something that you know.
LAC#5
Uh makes them feel a certain way, and, uh, they're willing to overlook all other evidence,
or any evidence that that points toward hey, like there are some cons of this too. There
are some negative implications.
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LAC#5
Well, so yeah, I'm very concerned about.
LAC#5
Uh, just, uh.
LAC#5
The level.
LAC#5
The level of use and abuse, and uh, particularly with these, uh.
LAC#5
This really.
LAC#5
Highly potent, uhm.
LAC#5
Yeah, all the above I I'm.
Leiker
Like the concentrates.
LAC#5
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Oh yeah, yeah. And like and with people of all ages, but especially younger people who
really that their brains aren't even like fully developed yet and they're getting.
LAC#5

LAC#5
Uh, addicted to these concentrates and you know these you know.
LAC#5
You know the marijuana ceases to be marijuana anymore on some level and really
becomes a.
Leiker
Qualities of producing a euphoric state, but as we think about synthetic cannibal, it kind
of cannabinoid's. What concerns do you have?
Leiker
You can.
LAC#5
Yeah, I think concerns that there's not a lot of research out there on them in comparison.

LAC#5
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Concerns that with a lot of these substances, all it takes is one time you know, and one
person could it, it could.
LAC#5
It could be very soothing and very helpful. Uh, another person. It could be really
enjoyable, will have you and another person that could. It could put them in the hospital.
LAC#5
With like the same amount, uhm, I mean?
LAC#5
We all have different brain chemistry. We all have different stuff going on and I I think
it's a.
LAC#5
Particularly with these synthetic.
LAC#5
Uh, substances. It's a. It's a roll of the dice as to, I mean, even if even if it's.
LAC#5
Just a one in.
LAC#5
A million chance that this could seriously.
LAC#5
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Hurt a person and it's probably even more common than that. I mean, there's still that
chance, and it could happen to anybody.
Leiker
So, as we close up, do you have any programmatic concerns?
Leiker
As to the methods, practices of color. Department of Health.
Leiker
In terms of treating cannabis.
LAC#5
No, not right now. I don't think so. I just I. I definitely appreciate this focus you have and
the and the work you're doing. I'm there's. There's a lot of there's a lot of gaps out there,
whether it's in the research.
LAC#5
Well, well, what have you, and, uh, I just think it's very important work and you know we
need more people who are who are passionate and committed to.
LAC#5
To doing the work.
Leiker
Well, thank you very much. That concludes our participant input. I'm going to come.

168

You know, do it with no shame in the room. Just accept and see if they want to. You
know, get involved in change talks for motivational interviewing and CBT and the other
thing.

